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In 2020, ovarian cancer still remains the "Biggest Enemy" faced by 
Gynecology Oncologists, due to the lack of biological and clinical tools for 
early diagnosis, high recurrence rates despite the recent introduction of 
targeted-therapies for the management of advanced disease, and 5-year 
overall survival below 40%. 
In particular, high grade serous ovarian cancer (HGSOC), recently 
classified as a Type II ovarian carcinoma, still accounts alone for the 80% 
of all ovarian cancer deaths. 
In light of these numbers and to the urgent need to reduce mortality from 
high grade serous ovarian cancer, in 2015 an international group of 
opinion leaders summarized a comprehensive list of priority issues which 
are still considered as “unmet needs” in the understanding of high grade 
serous ovarian cancer. Among these issues, the Authors identify the 
following biological landscapes to be explored for HGSOC patients’s 
future prognosis change: 
 1) to exploit HGSOC patients’ immune response and interaction between 
host immune system and tumor microenvironment; 
2) to analyse recurrent and end-stage disease samples, in order to shed 
light on acquired resistance mechanisms; 
3) to integrate all –omics data on individual samples with immune and 
other tumor microenvironment components in primary and recurrent 
samples.  
As a consequence, the research work carried out during this international 
PhD programme, and here discussed, aimed to add answers to these 
universally recognized priority issues in ovarian cancer understanding.  
In particular, the leading research line developed and carried out aimed to 
explore the modulation of tumor-derived neoangiogenesis during ovarian 
cancer progression and the role of anti-angiogenetic agents in reverting 
tumor immune suppressive circuit thus triggering host’s anti-tumoral 
immunological response.  
The 3 research studies here presented* were both carried out in the context 
of the “OCTIPS Consortium”, a 7th Framework Program research Project, 
funded by the European Commission in 2012, which currently holds in its 
biobank at Charité Medical University (Berlin, Germany) one of the largest 
European collection of paired primary and recurrent ovarian cancers 
samples; and in the context of the “Laboratory of Tumor Immunology and 
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Cell therapy Unit“ directed by Prof. Marianna Nuti, at Sapienza 
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Im Jahr 2020, bleibt der Ovarialkarzinom noch der schlimmste der gyneco-
onkologische Erkrankungen wegen diesen Gruenden: 
1. Fehlen einer wirksahmen screeing Methode  
2. hohe Rezidivrate, trozt der neuen “Target therapies” fuer die 
fortgeschrittenen Stadien dieser Krankheit 
3. kurzes 5-Jahren gesamt-Ueberleben (<40%) 
Bei dem fortgeschrittenen seroesen Eierstockkrebs (high grade serous 
ovarian cancer, HGSOC), kuerzlich genauso bekannt wie 
“Ovarialkarzinoma Typ II”,  liegt die Sterblichkeit bei 80% unter allen 
Todesfaelle vom Ovarialkarzinom. 
Im Jahr 2015, ist eine Liste von unbeantworteten Schwerpunkten in 
Ovarialkarzinoma von einer Internationalen Expertengruppe erstellt 
worden. 
Zu diesem Ziel, konzentrieren sich die Autoren auf den biologischen 
Hintergrund von HGSOC, wie folgt: 
1) Beziehung zwischen die Tumor-Mikroumgebung und das 
Immunsystem  
2) Gewebeanalysen zur Bestimmung von neu aufgetretenen Resistenz-
Mechanism 
3) Integration mit omics Daten von Proben mit immunologische und 
andere Tumor mivroinironment Komponenten. 
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Demensprechend ist die Forschung die waehrend diesem internationalen 
Phd Programm durchgefuehrt wurde, und hier discutiert wird, zur 
Vorstellung von Antworten zu diesen prioritaeren Fragestellungen zum 
Verstaendnis vom Ovarialkarzinom  gerichtet.  
Die folgende Forschungslinien wurden entwickelt: Untersuchung der 
Modulation von der Tumor gesteuerte Neoangiogenese zur Zeit der 
Progession von Ovarialkarzinom und von der Rolle die von den anti-
agiogenteischen Medikamenten in  der  Aenderung der Tumor assoziierte 
immunologische Hemmung spielen. 
Die 3 Studien die hier vorgestellt warden* sind im Rahmen von dem 
“OCTIPS Consortium” einen Forschungsprojeckt der von der 
Europaeische Kommission 2012 finanziert wurde, durchgefuehrt worden. 
Die Biobank vom OPTICS Consortium ist einer der groessten in Europa 
und enthaelt Proben von Ovarialkarzinome zur Zeit der Diagnose sowie 
zur Zeit vom Rezidiv und befindert sich an der Charite’ Medical 
University (Berlin, Germany). Zusaetzlich hat es eine Kollaboration mit 
dem Laboratory of Tumor Immunology and Cell therapy Unit“ unter der 
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After almost 20 years of carboplatin plus paclitaxel upfront treatment for 
ovarian cancer [duBois A, J Natl Cancer Inst 2003; Ozols RF, J Clin Oncol 
2003], the new millennium started with the successful introduction of 
targeted-therapies into the management of advanced disease [Burger RA, 
New Engl J Med 2011; Perren TJ, New Engl J Med 2011]. In 2011, the anti-
angiogenetic monoclonal antibody Bevacizumab, against Vascular 
Endothelial Growth Factor (VEGF), was the first to be incorporated into 
first-line management of advanced disease (EMA, December 2011). The 
second decade of 2000s is witnessing a new ovarian cancer paradigm shift 
based on the results recently obtained in first line setting by a new 
categories of targeted agents: the Poly (ADP-ribose) polymerase (PARP)-
Inhibitors (PARPi) [Moore K, New Engl J Med 2018; Coleman RL, New 
Engl J Med 2019; Gonzalez-Martìn A, New Engl J Med 2019; Ray-
Coquard I, New Engl J Med 2019], whose major target is primarily 
involved in the repair of single-strand DNA breaks [Ratnam K, Clin 
Cancer Res 2007]. 
Despite the successful incorporation of these target therapies into the 
management of advanced ovarian cancer, high-grade serous ovarian 
carcinoma (HGSOC) still accounts for the highest mortality rate among all 
ovarian cancer (OC) histotypes, with almost 80% of all new deaths from 
OC being caused by this distinct subgroup of ovarian tumours (Levanon 
K, J Clin Oncol 2008; Li J, J Hematol Oncol 2012; Cancer Genome Atlas 
Research Network 2011; Bowtell DD, Nat Rev Cancer 2015).  
More recently, the emerging role of immune checkpoint inhibitors (ICIs) 
in solid cancers is revolutionizing the scenario and the outcome of cure in 
oncology. The immune system, indeed, is a complex network where the 
several mechanisms and interactions involved are continuously 
discovered. Consequently, more than ever translational scientists are close 
to clinicians to better understand patients immune response to cancer in 
order to potentiate possible avenues of cure. 
Up to now, clinical results of these new immunomotherapy agents in OC 
are still limited, but suggest that they could benefit some patients with 
recurrent disease. The preliminary results of two phase III trials have 
shown that the addition of ICIs to chemotherapy does not improve 
progression-free survival. For this reason, there is a primary need to look 
for synergistic effects between ICIs and other active drugs in OC.  
In this scenario, international groups of opinion leaders have recognised 
the designing of new translational studies on recurrent and end-stage 
HGS tumour tissue samples as a key 'unmet need' in the understanding of 
HGSOC biology and clonal evolution, in order to maximize the effect of 
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available target therapies and possibly combine them with new 
immunotherapy drugs, with the final aim of enlarging the platform of OC 
patients, who could benefit from these new treatment categories (Bowtell 
DD, Nat Rev Cancer 2015). As a consequence, the research work carried 
out during this international PhD programme, and here discussed, aimed 
to add answers to these universally recognized priority issue in ovarian 
cancer understanding.  
In particular, the leading research lines were developed and carried out 
aimed to explore the modulation of tumor-derived neoangiogenesis 
during ovarian cancer progression and the role of anti-angiogenetic agents 
in reverting tumor immune suppressive circuit thus triggering host’s anti-
tumoral immunological response.  
The 3 research studies here presented were both carried out in the context 
of the “OCTIPS Consortium”, a 7th Framework Program research Project, 
funded by the European Commission in 2012, which currently holds in its 
biobank at Charité Medical University (Berlin, Germany) one of the largest 
European collection of paired primary and recurrent ovarian cancers 
samples; and in the context of the “Laboratory of Tumor Immunology and 
Cell therapy Unit“ directed by Prof. Marianna Nuti, at Sapienza 





After decades of paralysis in primary OC first-line chemotherapy 
treatment, incorporation of bevacizumab in the upfront regimen for 
advanced newly diagnosed disease (Burger RA, New Engl J Med 2011) 
has changed the 'standard of care paradigm' of advanced primary OC, 
although characterised by less survival impact than expected (Hansen JM, 
Eur J Cancer 2016; Aghajanian C, J Clin Oncol 2012; Pujade-Lauraine, J 
Clin Oncol 2014). Thus, understanding changes in the vasculature or 
identification of prognostic biomarkers of response to vasculature 
targeting is needed. Unfortunately, there are currently no predictive 
biomarkers to tailor bevacizumab treatment in OC patients. A full 
knowledge of molecular changes involving intratumoural vasculature 
from primary to recurrent HGSOC is still lacking and may provide new 
opportunities to: (1) tailor treatment with currently available anti-
angiogenetic agents, (2) shed light on acquired resistance mechanisms, 
and (3) develop new targeted therapies.  
In this context, the aims of the enclosed reseach studies were: 
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1) to identify changes occurring from primary to recurrent HGSOC in 
tumour tissue expression of the angiogenesis-associated biomarkers 
CD31, applied for detecting microvessels density (MVD) (Abufalia 
O, Gynecol Oncol 1999; Lertkiatmongkol P, Curr Opin Hematol 
2016; Stone P, Gynecol Oncol 2003) and VEGF-A (Hazelton P, 
Curr Oncol Rep 1999) by analysing a large cohort of paired 
primary and recurrent HGSOC tissue samples. Secondary 
endpoints included the correlation of biomarkers expression with 
patients’ clinico-pathological characteristics and survival data. 
(Ruscito I, Br J Cancer 2018); 
2) to investigate the correlation between the clinical response to 
bevacizumab-based chemotherapy and the improvement of 
immune fitness of multi-treated ovarian cancer patients 
(Napoletano C & Ruscito I, J Clin Med 2019); 
3) To give insight into new mechanism of immune-activation exerted 
by anti-angiogenetic agents commonly applied in oncology practice 
(Zizzari IG, Cancer Immun Res 2018). In particular this study, 
including only mRCC patients subjected to anti-angiogenetic TKI 
agents-based first line, give a proof of concept of the immune-
priming effects of anti-angiogenetic drugs and open new 
therapeutic avenues for their integration with ICIs in solid cancers, 
which is what is currently hoped and waited also in ovarian cancer 
setting. 
 
" Ruscito I et al., Br J Cancer. 2018 
♦ MATTER AND METHODOLOGY 
Samples Collection 
In Ruscito I, Br J Cancer 2018, paired cancer tissue samples belonging to 
HGSOC patients were collected during primary and secondary 
cytoreduction. Patients were retrospectively and consecutively selected 
from OCTIPS (Ovarian Cancer Therapy–Innovative Models Prolong 
Survival, Agreement No.279113-2) Consortium database. Included 
patients underwent both primary (pOC) and recurrent (rOC) surgery in 
one of the European Gynaecologic Oncology referral Centers of the 
following Institutions: Charité Universitätsmedizin Berlin, Germany; 
Catholic University of Leuven, Belgium; Imperial College, London, UK; 
University of Edinburgh, UK; University Medical Center Hamburg- 
Eppendorf, Germany. Inclusion criteria were: availability of paired 
primary and recurrent cancer tissue samples from HGSOC patient 
together with clinical annotation. Exclusion criterion was: neoadjuvant 
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chemotherapy treatment, due to the need to analyse primary chemo-naïve 
tumours. Approval from each local ethics committee was obtained 
(EK207/2003, ML2524, 05/Q0406/178, EK130113, 06/S1101/16). All included 
samples underwent central histopathological assessment to confirm 
HGSOC histology and ensure tumour tissue content and quality. 
Patients’ clinico-pathological data, including somatic-BRCA status from 52 
included patients, were retrieved from OCTIPS Consortium database.18 
GCIG criteria were applied to define platinumresistance and platinum 
sensitivity.19 RECIST Criteria were applied during patients’ follow-up to 
define HGSOC relapse.20 No residual tumour was defined 
intraoperatively by the surgeon in case no macroscopic tumour could be 
detected at the end of cytoreduction. In order to investigate any 
association between different tumour vasculature profiles and 
intratumoural immune infiltrate in both pOCs and rOCs, MVD and/or 
VEGF profiles were matched with previous OCTIPS data on tumour 
infiltrating lymphocytes (TILs), assessed through the 
immunohistochemical expression of CD3, CD4, and CD8 biomarkers, as 
previously reported (Stanske M, Neoplasia 2018). Furthermore, 
immunosuppressive TILs were evaluated through the expression of T-
regulatory cells-specific biomarker FoxP3, using the mouse anti-human 
FOXP3 antibody (clone ab20034; Abcam, Cambridge, MA, USA, 1:200, 1.5 
h at room temperature).  
 
Methods 
The immunohistochemistry methodology was applied. Tissue microarrays 
(TMA) were constructed for immunohistochemical staining. Each primary 
and recurrent tumour tissue sample was represented within the TMA by 
two tumour cores, each containing at least 90% of cancer cells. Sections 
from TMA were deparaffinised in xylol, rehydrated in graded alcohol, and 
boiled in pressure cooker for 5 minutes in citrate buffer (pH = 6), for CD31 
staining, or in EDTA (pH = 9), for VEGF staining. Rabbit anti-human CD31 
antibody (clone ab32457; Abcam, Cambridge, MA, USA) and rabbit anti-
human VEGF-A antibody (clone A-20; Santa Cruz Biotechnology, Dallas, 
TX, USA) were diluted 1:20 and 1:250, respectively, and incubated on 
slides for 60 minutes at room temperature. Bound antibodies were 
visualised using DAKO Real Detection System and DAB + (3,3′ - 
diaminobenzidine; DAKO, Glostrup,Denmark) as a chromogen. Finally, 
the slides were co-stained with hematoxylin. CD31 stained samples were 
assessed in terms of MVD. MVD was determined by averaging the 
number of vessels from three distinct areas of tumour with highest vessels 
density examined at ×200 magnification (Goodheart M, Gynecol Oncol 
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2002; Crasta J, Int J Gynecol Pathol 2011; Nadkarni N, Cancer Lett 2013). 
Samples were further classified into 'MVDhigh' (≥16.3 vessels) or 
'MVDlow' (<16.3 vessels), establishing the cut-off level of MVD count for 
dichotomisation at first quartile (primary samples), being the value able to 
maximise difference in OS hazard ratio (Goodheart M, Gynecol Oncol 
2002; Nadkarni N, Cancer Lett 2013; Bais C, J Natl Cancer Inst 2017). 
For VEGF staining evaluation, the number of stained tumour cells within 
the whole TMA cores (0% = 0; 1–10% = 1; 11–50% = 2; >50% = 3) was 
multiplied with the intensity of staining (negative = 0; weak = 1; moderate 
= 2; strong = 3) (Mukherjee S, J Clin Diagn Res 2017) resulting in a 
semiquantitive immunoreactivity score (IRS) ranging from 0 to 9. Samples 
were classified as 'VEGF(+)', for VEGF-high tumour expression (IRS = 4–9), 
or as 'VEGF(−)', for absent/weak focal staining (IRS = 0–3). As positive 
control for IHC were used human liver sections. Samples staining was 
assessed independently by two co-authors (IR and SDE). 
 
Statistical Ananlysis 
Statistical analysis was performed using SPSS version 22.0 (SPSS 
Inc,Chicago,IL,USA). Difference in biomarker expression between pOCs 
and rOCs was assessed through the correlation test (Spearman coefficient, 
2-tailed) and 'Wilcoxon signed rank' nonparametric test for related 
samples. Fisher’s exact test was applied to correlate MVD and/or VEGF 
tumour expression with patients’ clinico-pathological categorical data. 
Patients’ progression-free interval (PFI), progression-free survival (PFS), 
and overall survival (OS) were identified through Kaplan–Meier analysis 
(Log-Rank test). PFI was defined as the time interval from the last 
adjuvant chemotherapy to relapse, whereas progression-free survival 
(PFS) was established as the time interval between first recurrence 
diagnosis and tumour progression. Univariate and multivariate survival 
analyses were performed applying Cox-regression model. Multivariable 
models were obtained among variables reporting a p-value ≤ 0.1 in 
univariate analysis. p-values ≤ 0.05 were evaluated statistically significant. 
♦ RESULTS 
A total of 222 intra-patient paired primary and recurrent HGSOC tissue 
samples derived from 111 patients were included. To note, only 2/111 
(1.8%) patients received bevacizumab in front-line chemotherapy, thus the 
staining of recurrent samples have not been influenced by first-line 
administration of anti-angiogenetic compounds. 
MVD staining 
MVDhigh staining was detected in 75.7% (84/111) of pOC and in 51.4% 
(57/111) of rOC, whereas MVDlow staining was found in 24.3% (27/111) 
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and in 48.6% (54/111) of pOC and rOC, respectively. MVDlow staining 
was twice as prevalent in relapsed tumours compared to primary disease 
(p = 0.0003, Fisher’s exact test). Nevertheless, globally, pairwise analysis 
revealed no tendency towards a change in MVD to higher or lower levels 
in recurrent samples (p = 0.935, Wilcoxon test; Fig. 1e), as well as no 
significant correlation between pOCs and rOCs in MVD was reported 
(Spearman correlation, p = 0.920; Spearman coefficient: 0.01). 
VEGF-A expression 
The same percentage of VEGF(+) (20.7%, 23/111) and VEGF(−) (79.3%, 
88/111) tumour samples was found between pOCs and rOCs, respectively, 
(p = 1, Fisher’s exact test), although no significant correlation between 
pOCs and rOCs VEGF IRS values could be observed (p = 0.505, Spearman 
coefficient 0.06). Furthermore, pairwise analysis confirmed no tendency 
towards a change in VEGF IRS levels at tumour relapse (p = 0.121, 
Wilcoxon test). 
MVDhigh and VEGF(+) co-expression in pOCs vs rOCs. 
MVDhigh and VEGF(+) co-expression was more frequent in pOCs group 
(22/111, 19.8%) compared to rOCs (9/111, 8.1%) (p = 0.02, Fisher’s exact 
test).  
Relationship between MVD and/or VEGF-A expression with TILs. 
Results showed that MVDhigh levels in pOCs samples were associated 
with higher CD3(+) (p = 0.029, Mann–Whitney test) and CD8(+) (p = 0.013) 
effector TILs, but not with a higher FoxP3(+) (p = 0.443) T-regulatory cells 
infiltrate. To note, the correlation between MVD and CD3(+)/CD8(+) TILs 
disappeared at tumour recurrence. No significance between pOCs or rOCs 
VEGF expression or MVDhigh + VEGF(+) co-staining with TILs was 
reported. 
MVD and/or VEGF-A profiles and patients’ clinico-pathological factors 
To note, VEGF(+) primary HGSOCs and MVDhigh/VEGF(+) primary 
samples were most frequently encountered among somatic-BRCA-
mutated tumours compared to somatic- BRCA wild-type cases (p = 0.019, 
Fisher’s exact test). No further significant associations between different 
intratumoural residual tumour after primary debulking or first-line 
platinum response was identified. Decrease of VEGF expression in rOCs 
was observed only in BRCA-mutated patients (p = 0.053, Wilcoxon test), 
although this association did not reach statistical significance.  
Survival 
Patients, whose pOCs resulted MVDhigh, VEGF(+) or co-stained for both 
biomarkers, were found to have a significantly improved OS compared to 
patients without these intratumoural profiles at primary disease. In 
particular, median OS for MVDhigh and MVDlow patients was 67 and 46 
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months, respectively (p = 0.019), median OS for VEGF(+) and VEGF(−) 
patients resulted 76 vs 52 months, respectively (p = 0.036), while median 
OS for patients with co-stained pOCs was 76 months, compared to 52 
months in women without co-expression (p = 0.021). On the contrary, no 
influence of pOCs or rOCs MVD and/or VEGF expression on patients’ 
time to progression after primary (PFI) or first recurrent disease (PFS) was 
reported. Multivariate analysis for OS and PFI was carried out on the 
whole patients’ population (n = 111) and also on the subgroup of patients 
(n = 52) with known tumour somatic-BRCA status. VEGF-A was not found 
to be an independent prognostic factor for OS anymore when considering 
also somatic-BRCA mutational status. Only somatic-BRCA mutation (HR: 
0.354, CI 95%: 0.133–0.994; p = 0.038), high CD4(+) TILs (HR: 0.997, CI 95%: 
0.995–1.000; p = 0.038) and first-line platinum response (HR: 0.216, CI 95%: 
0.051–0.991; p = 0.037) were found to independently improve HGSOC 
patients’ OS. When analysing the Platinum free-interval (PFI) in patients 
with or without BRCA somatic mutations, advanced FIGO stage (HR: 
18.261, CI 95%: 1.28–260.17; p = 0.032) and low CD4(+) TILs (HR: 0.996, CI 





" Napoletano C & Ruscito I, J Clin Med. 2019 
♦ MATTER AND METHODOLOGY 
Samples Collection 
In Napoletano C & Ruscito I, J Clin Med 2019, 20 consecutive recurrent 
ovarian cancer patients were retrospectively selected from “Sapienza” 
PBMC sample collection at the “Laboratory of Tumor Immunology and 
Cell Therapy Unit”, Department of Experimental Medicine (Sapienza 
University of Rome, Italy—Ethical Committee approval, protocol n° 
703/2008; date of approval 07/24/2008). PBMCs belonging to all available 
multi-treated platinum-resistant ovarian cancer patients subjected to 
intraperitoneal (i.p.) bevacizumab-based chemotherapy as compassionate 
use were selected (Bev group; 10 patients), together with 10 patients (Ctrl 
group) that received non-bevacizumab-based chemotherapy. Inclusion 
criteria were: primary diagnosis of advanced epithelial serous ovarian 
cancer; having been subjected to at least three previous chemotherapy 
lines; diagnosis of tumor progression confirmed by CT scan; presence of 
malignant ascites; life expectancy of at least three months; and availability 
of at least three PBMCs samples per patient collected during the course of 
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bevacizumab-based versus non-bevacizumab-based chemotherapy. 
Furthermore, patients of the Bev group were matched with the Ctrl group 
patients for age, tumor grading, FIGO stage, type of primary	 treatment 
strategy (primary debulking surgery versus neoadjuvant chemotherapy 
followed by interval debulking surgery), tumor residual at first surgery, 
and type of recurrence at the time of blood sampling in order to minimize 
selection bias and avoid misinterpretations of results. Ten patients were 
identified as the ones that had received i.p. bevacizumab 5 mg/kg every 21 
days immediately after paracentesis for treatment of malignant ascites 
[Kobold S, Oncologist 2009; Bellati F, Invest New Drugs, 2010] plus 
intravenous (intravenous injection, i.v.) monochemotherapy (cisplatin) 
[Shamsunder S, J Obstet Gynaecol Res 2000], while 10 other patients 
were identified as been treated with i.v. monochemotherapy alone 
(paclitaxel, topotecan, pegylated liposomal doxorubicin, cisplatin). 
Patients’ clinicopathological data were retrieved from clinical charts. 
Disease progression was defined basing on the response evaluation 
criteria in solid tumors (RECIST) [Eisenhauer E.A, Eur. J. Cancers 2009]. 
This retrospective study received institutional review board (IRB) 
approval and was carried out following the rules of the Declaration of 
Helsinki of 1975. 
 
Methods 
• PBMC Purification 
PBMCs were isolated from 12 to 14 mL of peripheral blood by Ficoll 
Hypaque gradient (1077 g/mL; Pharmacia LKB, Sweden), obtaining a yield 
between 10 × 106 and 12 × 106 cells for each drawing and cryopreserved 
until use. Samples were taken before therapy (T0) and after three (III) and  
six (VI) cycles of therapy. 
• Cell Phenotype 
Cell phenotype staining was performed using several directly conjugated 
monoclonal antibodies (MoAbs). T cells were incubated with the anti CD8-
PE-Cy5.5 (RPA-T8 clone), anti-CD3-PE (UCHT1 clone), anti-CCR7-FITC 
(150503 clone), and anti-CD45RA-APC (HI100 clone) MoAbs, all from 
Becton Dickinson (Franklin Lakes, NJ, USA). Tregs were stained with the 
anti-CD25-PE (MA251clone), anti-CD45RA-APC (HI100 clone), anti-CD4-
FITC (RPA-T4 clone), and anti-FOXP3-Alexa 647 (259D/C7 clone) MoAbs, 
all from Becton Dickinson. Cells were incubated with the conjugated 
MoAbs targeting extracellular antigens for 30 min at room temperature 
(RT) as indicated by the manufacturer’s instruction. The staining of 
intracellular antigen FOXP3 was performed after the cells’ 
permeabilization with the Human FOXP3 Buffer Set (Beckton Dickinson, 
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Franklin Lakes, NJ, USA). After washing, at least 1 × 104 events were 
evaluated using a FACSCanto flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ, USA) running FACSDiva data acquisition and analysis 
software (Becton Dickinson, Franklin Lakes, NJ, USA). The percentages of 
CD4 and CD8 T cells were calculated with respect to the entire CD3 T cell 
population, while the percentage of Treg was evaluated with respect to 
CD4 T cells. 
• Intracellular Cytokine Staining 
T cells were stimulated with the anti-CD3 (OKT3 clone, 1 µg/mL) 
(eBioscence, San Diego, CA, USA) and anti-CD28 (CD28.2 clone, 5 µg/mL) 
(BioLegend, San Diego, CA, USA) MoAbs for 16 h at 37 °C in the presence 
of Brefeldin (Sigma-Aldrich, St. Louis, MO, USA) (10 µg/mL). The staining 
of IL-10 positive cells was carried out by fixing the cells with 2% 
paraformaldehyde (Sigma-Aldrich, Saint Louis, MO, USA). Cells were 
than washed with phosphate-buffered saline (PBS) without Ca2+ and 
Mg2+ + 0.5% saponin (Sigma-Aldrich, Saint Louis, MO, USA) + 10% fetal 
bovine serum (FBS) (Sigma-Aldrich, Saint Louis, MO, USA) and incubated 
for 30 min with anti-IL-10-PE (JES3-19F1 clone) (BioLegend, San Diego, 
CA, USA) MoAb. Cells were analyzed using a FACSCanto flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA) running FACSDiva data 




Statistical analysis was performed using Graphpad Prism version 6 
(Graphpad Software, Inc., San Diego, CA, USA). Descriptive statistics 
(average and standard deviation) were used to describe different groups 
of continuous data. Student’s t-test was used to compare groups of 
continuous variables. Groups of categorical data were compared using the 
Fisher’s exact test. Significance is indicated when p ≤ 0.05. 
 
♦ RESULTS 
Patients’ Characteristics and Clinical Response 
Twenty patients met all inclusion criteria and were included in the study. 
As a result of patient matching, no differences in terms of 
clinicopathological variables as well the Eastern Cooperative Oncology 
Group (ECOG) performance status could be identified between the Bev 
group and the Ctrl group. At the time of blood sampling for 
immunological analysis, 12/20 women (60%) presented intraperitoneal 
tumor progression, whereas the remaining 3/20 (15%) and 5/20 (25%) 
patients were diagnosed with intraperitoneal plus retroperitoneal disease 
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worsening and widespread tumor dissemination, respectively. From a 
clinical point of view, and as confirmed by serial Ca125 serum levels, 50% 
(10/20) of patients were judged responders to chemotherapy after six 
cycles of treatment and were equally distributed in each group of 
interventions (5/10 in the Bev group and 5/10 in the Ctrl group). 
Bevacizumab-Treated Patients Showed a Different Immunological 
Signature Compared with the Control Group 
To understand whether bevacizumab treatment impacts the 
immunological status of ovarian cancer patients, the modulation of 
circulating CD4 and CD8 T cells was firstly analyzed in the Bev group and 
the Ctrl group before (T0) and after III and VI cycles of treatments. Both 
CD4 and CD8 T cells played a critical role in the activation of an effective 
antitumor immunity. CD8 lymphocytes exerted their cytotoxic activity by 
eliminating tumor cells, while CD4 T lymphocytes sustained and 
maintained a CD8 T cell response by cytokine production [Lanzavecchia, 
A. Science 2000, 290, 92–97]. A deficiency in the activation of one of these 
two populations induced the development of a failed immunity against 
the tumor. Results obtained from the cancer patients showed that 
therapies did not modify the percentage of CD4 and CD8 lymphocytes in 
both groups at different time points. CD4 T cells were significantly higher 
in the Bev group at T0 and III compared with the Ctrl goup, although this 
difference disappeared at the end of VI cycles. No difference was observed 
in CD8 T cells between the two groups, although the ratio CD4/CD8 
remained high (>1) up to VI cycles in both groups, suggesting a 
predominance of CD4 T cells during therapies. CD8 and CD4 T cells were 
concurrently analyzed for the expression of CCR7 and CD45RA 
molecules, which identify four different lymphocyte subsets: effector 
(CCR7−CD45RA+), naïve (CCR7+CD45RA+), central memory 
(CCR7+CD45RA−), and effector memory (CCR7−CD45RA−) T cells. 
Analyzing these T cell subpopulations in the Bev and Ctrl group patients, 
no significant difference throughout the treatment in each patient group 
and between the two groups were found. 
Finally, the percentage of Tregs was also examined following the 
expression of CD4, CD25, and FOXP3 markers. In cancers, Tregs represent 
one of the most important T cell populations as they are able to suppress 
the activation and/or expansion of antitumor CD4 and CD8 T cells 
through cell–cell contact or by cytokine release [10]. A high percentage of 
Tregs is associated with a poor prognosis in different types of solid tumors 
[Shou J, BMC Cancer 2016; Zhao S, Oncotarget 2016]. In our setting of 
patients, the results demonstrated that the Ctrl group showed a significant 
decrease in total Tregs from T0 to VI cycles (36% vs. 31%, p = 0.03), while 
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no difference was found in the Bev group throughout the therapy. Total 
Tregs were further analyzed according to the combined expression of 
CD25, FOXP3, and CD45RA markers, which identifies three important 
Treg subpopulations [10]: resting Treg (CD25+CD45RA+FOXP3+: rTregs), 
activated Tregs (CD25highCD45RA-FOXP3-: aTregs), and 
cytokinesecreting Tregs with no suppressive activity (CD25+CD45RA-
FOXP3+: nsTregs). aTreg have been 
described as terminally differentiated cells that rapidly die after exerting 
their suppressive activity, whereas rTreg proliferate and convert into 
aTreg both in vitro and in vivo [10]. The analysis revealed that 
bevacizumab-treated patients showed a lower percentage of aTregs and 
rTregs compared with the Ctrl group at T0. This difference persisted until 
III cycles of treatment in the rTreg subset and disappeared after VI cycles, 
suggesting that these patients exhibited a less suppressive immunological 
profile compared with the Ctrl group at the beginning and in particular 
after III cycles of therapies. 
Bevacizumab-Treated Patients Showed a Discrete CD4 Effector T Cell 
Population throughout the Treatment. 
Patients belonging to the Bev group and the Ctrl group were then divided 
in clinically responders (R) and clinically nonresponders (N-R) to therapy 
according to RECIST (Table S1). The modulation of CD4 and CD8 T cell 
was initially evaluated in R and N-R patients of both groups, followed by 
the analysis of the different T cell subsets (Figure 2). The results 
demonstrated that the CD8 T cells derived from bevacizumab-treated 
patients were not differently modulated in R and NR patients, while the 
CD4 T cells appeared to be significantly higher in the N-R group at the 
beginning and after VI cycles of treatment. Conversely, in the Ctrl group, 
the CD8 T cells seemed to be significantly higher after VI cycles in the R 
patients compared with the N-R ones, while no significant difference was 
observed in the CD4 T cell population.  
Lymphocytes were also analyzed according to the expression of CCR7 and 
CD45RA molecules. The results demonstrated that in the Bev group and 
the Ctrl group, the percentage of CD4 effector T lymphocytes in R patients 
was higher compared with N-R patients at T0. This difference persisted 
until the end of the therapies for bevacizumab-treated patients, while it 
had already disappeared after III cycles of therapy in the control group. 
This suggests that Bev treatment, by favoring the normalization of the 
tumor vasculature [13], improves and sustains the circulation of effector T 
cells. The other CD4 T cell subsets and the CD8 T cell populations were 
not significantly modified by treatments.  
Tregs Were Modulated in Bevacizumab-Treated Patients during 
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Therapies. 
To assess whether the treatment schedule and/or the clinical response 
could be associated with the modulation of the Treg subsets, the 
percentage of circulating Tregs after III or VI treatment cycles were 
compared with the baseline value at T0, and the analysis was expressed as 
fold increase (%TregIII/%TregT0 or %TregVI/%TregT0) (Figure 4). After 
III cycles of treatment, the level of the entire Treg population was 
significantly higher in R patients compared with N-R patients in the Bev 
group. This increase was ascribed to the nsTreg subset being significantly 
higher in R compared with N-R patients. These differences between R and 
N-R patients disappeared after VI cycles of bevacizumab treatment. In 
contrast, the control group did not show any difference in the percentage 
of Tregs between R and N-R patients during therapies, and no difference 
between the Bev and Ctrl patients was observed. 
Bevacizumab-Treated N-R Patients Had Higher Level of IL10+ T Cells 
Compared to R Patients. 
Because IL10, such as TGFβ, is one of the most important cytokines 
released by Tregs [14] that is able to downregulate Th1 cytokine 
production and block NF-κB activity [15], T cell derived from patients in 
the Bev group were analyzed for their capacity to produce IL10 as 
intracellular staining. These patients exhibited a significant increase in 
IL10+ cells from T0 up to VI cycles of therapy. Analyzing the data as fold 
increase of the percentage of IL10+ cells after III and VI cycles of therapy 
compared with T0 (%IL10III/%IL10T0 or %IL10VI/%IL10T0) between R 
and N-R patients, significant high levels of IL10 were found in N-R 
patients after III cycles, suggesting an enhancement of the 
immunosuppression during the bevacizumab treatment in this group. 







" Zizzari IG et al., Cancer Immunol Res. 2018 
♦ MATTER AND METHODOLOGY 
Samples Collection 
In Zizzari IG, Cancer Immun Res 2018, peripheral blood mononuclear 
cells (PBMCs) of 6 metastatic Renal Cancer Cell (mRCC) patients (Ethical 
Committee Protocol, RIF.CE: 4181) were isolated from blood samples (50 
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mL) by Ficoll–Hypaque at different times (Ethical Committee Protocol, 
RIF.CE: 4181): before treatment with sunitinib or pazopanib (T0), during 
treatment (T1: 1 month of treatment, T2: 2 months, T3: 3 months etc.) and 
during progression. PBMCs isolated from healthy donors were also 
collected to consititute a control group. 
 
Methods 
• Generation of DCs 
Human monocyte-derived DCs were generated from PBMCs) of healthy 
donors and of mRCC patients. Monocytes (CD14þ) were purified from 
PBMCs after Ficoll–Hypaque gradient (1,077 g/mL; Pharmacia LKB) by 
Human CD14-Positive Selection Kit (StemCell Technologies) and cultured 
(5 x 105 cells/mL) in RPMI 1640 (Hyclone) supplemented with 2 mmol/L 
L-glutamine, penicillin 100 U/mL, streptomycin 100 mg/mL (Sigma-
Aldrich), with 5% heat-inactivated Fetal Calf Serum (FCS; Hyclone). Fifty 
ng/mL rhGM-CSF (R&D Systems) and 2,000 U/mL rhIL4 (R&D Systems) 
were added at day 0 and 2. Immature DCs (iDCs) were collected at day 5 
and matured with cytokine cocktail (rhIL1b, IL6, TNFa and PGE2; all 
purchased by R&D Systems) for 16 hours. Sunitinib (50 ng/mL; Sigma-
Aldrich) and pazopanib (19 mg/mL; Sigma-Aldrich) were dissolved in 
dimethyl sulfoxide (DMSO; Euroclone) and added to the culture during 
DC differentiation. 
• Immune phenotype 
DC phenotype was analyzed by flow cytometry using the following 
monoclonal antibodies (mAb): anti–HLAII-DR-FITC, anti–CD86-FITC, 
from BD Biosciences, anti–CD14-PE, anti–CCR7-FITC, anti–CD83-PE, 
anti–CD40-PE, anti–PD-L1-PE from BioLegend and anti–VEGR-1 from 
R&D Systems. MoAbs anti–IgG1-FITC and anti–IgG1-PE (BioLegend) 
were used as isotype controls. For immune profile evaluation, PBMCs 
were isolated from blood samples (50 mL) from six mRCC patients by 
Ficoll– Hypaque at different times: before treatment with sunitinib or 
pazopanib (T0), during treatment (T1: 1 month of treatment, T2: 2 months, 
T3: 3 months etc.) and during progression. Various T-cell subsets were 
analyzed:  
T-cell subpopulations: anti–CD3-APC-H7/CCR7-PE/CD8 
PerCp-Cy5.5/CD45RA-BB15.  
Treg cells: anti–CD4-APC-H7/CD25-PE/CD45RA-BB15/FoxP3- 
Alexa647.  
T-cell activation/proliferation: anti–CD3-APC-H7/CD8-PerCp- 
Cy5.5/CD137-APC/Ki67-PeCy7. 
T-cell exhaustion: anti–CD3-APC-H7/CD8-PerCpCy5.5/PD1- 
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PE/CTLA4-APC/Tim3-BB15. 
All mAbs were purchased by BD Biosciences and BioLegend. Flow 
cytometric analysis was performed using FACSCanto flow cytometer 
running FACS Diva data acquisition and analysis software (BD 
Biosciences).  
• Microvesicle isolation 
Microvesicles were isolated from supernatants of DCs differentiated with 
and without suninitib and pazopanib. Supernatants were centrifuged at 
13,000 x g for 30 minutes at 4°C. Microvesicles were then stained with 
anti–PD-L1 (BioLegend) and acquired by FACSCanto flow cytometer and 
analyzed by FACS Diva software. Anti–IgG1-PE (BD Biosciences) was 
used as isotype control. Fluorescent Nile Red Particles (0.1–0.3 mm, 
Spherotech Inc.) were used as size control. 
• Western blot analysis 
Immature DCs and mature DCs (iDCs and mDCs, respectively) with and 
without sunitinib and pazopanib were lysed using the NP-40 solution 
(Biocompare) in the presence of phenylmethylsulfonyl fluoride (1 mmol/L, 
PMES) and protease inhibitors (1X; Sigma). Proteins obtained were 
quantified by Bradford assay, were resolved using 4% to 12% SDS-PAGE 
gel and transferred to nitrocellulose. After blocking, membranes were 
incubated with rabbit anti–b-catenin (Bethyl Laboratories Inc.; 1:1,000), 
rabbit anti-pErk42/44 (Erk1/2; Cell Signaling Technologies; 1:1,000), mouse 
anti–b-actin (Cell Signaling Technologies; 1:1,000) and mouse anti–NF-kB 
(p105/p50; Cell Signaling Technologies; 1:1,000), followed by peroxidase-
conjugated goat anti-rabbit or anti-mouse IgG (HþL; Jackson Immuno 
Research Laboratories; 1:20,000). Protein bands were detected with 
Immobilon Western (Millipore Corporation) following the manufacturer's 
instructions. The density of protein bands was analyzed by Image J 
software and was normalized in terms of average intensity of bands of 
each protein per average intensity of bands of b-actin. 
• Endocytosis assay 
FITC-dextran (1 mg/mL; Molecular Probes) was added to untreated iDCs 
and mDCs and differentiated with sunitinib and pazopanib for 2 hours at 
37°C. After washing, cells were acquired by FACSCantoII flow cytometer 
and analyzed by FACSDiva software. DCs incubated with FITC-dextran 
for 2 hours at 4°C were used as negative controls. 
• Cytokine production 
Culture supernatants from iDCs and mDCs untreated or differentiated 
with sunitinib and pazopanib and sera from mRCC patients were 
collected and analyzed using the ProcartaPlex Human Inflammation Panel 
(20 Plex; eBioscence). Samples were measured by BioPlex Magpix 
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Multiplex Reader (Bio-Rad) and data analysis was performed using 
Bioplex Manager MP software (Bio-Rad). 
• T-cell proliferation 
T lymphocytes were purified from Ficoll–Hypaque gradient (1,077 g/mL; 
Pharmacia LKB) followed by CD3 immunomagnetic isolation (StemCell). 
T cells were then cocultured in a 96-well round-bottom microplate 
(Costar) with allogeneic iDC and mDCs differentiated with and without 
sunitinib and pazopanib (DCs: T cells, 1:5) in the presence of PHA (5 
mg/mL) for 4 days at 37°C. T cells were pretreated with 
CarboxyFluorescein Succinimidyl Ester (1 mmol/L, CFSE; Life 
Technologies) and cell proliferation was monitored through progressive 
halving of fluorescence using FACSCantoII flow cytometer and analyzed 
by FACSDiva software (BD Biosciences). Results were reported as the 
percentage of proliferation increase of T cells cultured with DCs treated 
with sunitinib and pazopanib compared with T cells cultured with DCs 
alone. T cells were also cultured in 6-well round-bottom microplates 
(Costar) in the presence of sunitinib (50 ng/mL) and pazopanib (19 
mg/mL) up to 24 hours. Proliferation was evaluated by FACSCantoII flow 
cytometer and analyzed by FACSDiva software. 
• Statistical analysis 
Descriptive statistics (average and standard deviation) were used to 
describe the various data. ANOVA test was used to analyze statistical 
differences between three groups. Student paired t test was used to 
compare two groups. Significance is indicated when the P value was less 
than 0.05. 
♦ RESULTS 
Pazopanib improves DC activation and increases expression of DC-
maturation markers. 
To investigate the capacity of TKIs to influence DC differentiation and 
maturation in vitro, the expression of CD14, HLA-DR, CD86, CD83, CCR7 
and CD40 was evaluated by flow cytometry on monocyte-derived DCs of 
healthy donors. Untreated DCs were used as control. The exposure to 
concentrations of sunitinib and pazopanib found in plasma affected the 
phenotype of immature and mature DCs differently. Sunitinib did not 
affect DC differentiation and maturation, but DCs cultured in the presence 
of pazopanib were more activated. Pazopanib modified iDC phenotype, 
significantly increasing the expression of HLA-DR and CD40 molecules, 
compared with that of iDCs alone (HLA-DR P < 0.01) and iDC treated 
with sunitinib (HLA-DR P < 0.05; CD40 P < 0.05; Fig. 1A). The average 
values of mean fluorescence intensity (MFI) indicated upregulation of 
CD83 in DCs differentiated with pazopanib. On the other hand, CD14 
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expression was downregulated by pazopanib during differentiation. 
Similar results were obtained after DC maturation. mDCs cultured in 
presence of pazopanib significantly upregulated the expression of CCR7 
and CD40 molecules compared with untreated mDCs (CCR7 P < 0.05; 
CD40 P <0.05) and sunitinib-treated mDCs (CCR7 P < 0.05), suggesting 
that pazopanib enhances activation status of both immature and mature 
DCs. VEGF-R1 expression, which is the target of both TKIs, was 
unaltered by treatment of DCs with pazopanib or sunitinib. 
PD-L1 is downregulated in pazopanib-generated DCs. 
The capacity of DCs to stimulate T cells depends on the balance between 
costimulatory and coinhibitory signals. Increased expression of 
costimulatory marker such as CD40 or CD83 can facilitate T-cell 
activation, whereas increased expression of inhibitory markers such as 
PD-L1 contributes to T cell-negative regulation (Steinman RM. Apmis 
2003). To evaluate the expression of coinhibitory signals in DCs in 
response to TKI treatment, we analyzed the expression of the PD-L1 both 
on DCs and on shed microvesicles. During iDC differentiation, only 
pazopanib began to decrease PD-L1 expression, compared with untreated 
DC and DCs differentiated with sunitinib (Fig. 2A). The decrease in 
expression became significant (P < 0.01) in DCs after maturation. 
Microvesicles released by the DCs also showed a decrease in PD-L1 
expression: PD-L1 expression on microvesicles released by DCs treated 
with pazopanib was lower than that on microvesicles obtained by 
untreated DCs and DCs treated with sunitinib. The difference in 
expression of PD-L1 between microvesicles of mDCs and mDCs treated 
with pazopanib was statistically significant (P < 0.05). 
Pazopanib treatment reduces immunosuppression downregulating IL10 
production by DCs. 
The production of cytokines such as IL10 and IL12 during DC maturation 
can influence the capacity of DCs to alter Th1 or Th2 immune responses 
(Moser M, Nat Immunol 2000). Several chemokines released by DCs, such 
as CXCL-10, promote tumor-reactive effector T-cell recruitment (Pfirschke 
C, Cancer Cell 2017). Thus, we evaluated cytokines and chemokines 
released by untreated DCs and DCs treated with TKIs. We observed a 
significant reduction (P < 0.05) of IL10 in iDCs and mDCs treated with 
pazopanib compared with untreated DCs (both iDC and mDCs) and DCs 
treated with sunitinib (both iDC and mDCs). The balance between 
IL12/IL10 and CXCL-10/IL10 favored immune activation when DCs were 
generated with pazopanib. 
Pazopanib-treated DCs are able to increase T-cell activity. 
DCs must possess specialized features to act as good antigenpresenting 
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cells. In addition to expression of costimulatory molecules and release of 
cytokines, other indicators of DC function and quality include their 
capacity for endocytosis and T-cell activation. The exposure to maturation 
stimuli induces changes including downregulation of endocytosis and 
increase of antigen presentation to T cells. We evaluated the endocytic 
capacity of DCs treated with TKIs and untreated DCs by fluorescein 
isothiocyanate (FITC)-dextran uptake and followed by flow cytometry. 
We determined the ratio of the fluorescence from positive (dextran uptake 
obtained after 2 hours at 37°C) and negative (dextran uptake after 2 hours 
at 4°C) samples. The results show that pazopanib reduced endocytosis 
capacity by 29% for iDCs treated with pazopanib compared with 
untreated DCs (1.42 ratio vs. 2, respectively), and by 40% compared with 
iDCs treated with sunitinib (1.42 vs. 2.33). The trend persisted after 
maturation: the endocytic capacity of pazopanib-treated mDCs was 42% 
lower than that of mDCs (0.8 ratio vs. 1.37) and 57% lower than that of 
sunitinib-treated mDCs (0.8 vs. 1.82). We then analyzed the capacity of 
DCs to stimulate the proliferation of allogeneic T cells. Lymphocytes, 
pretreated with CFSE, were cocultured with DCs and proliferation was 
evaluated after 4 days through progressive halving of fluorescence by 
flow cytometry. The results, plotted as percentage of fold increase (% of 
proliferation obtained as ratio between T cells stimulated by pazopanib-
DCs/DCs or sunitinib-DCs/ DCs), showed that when DCs were 
differentiated in the presence of pazopanib, they acquired a greater 
capacity to stimulate T cells than either untreated DCs (20% fold increase 
for alone for 24 hours in the presence of either TKI. 
Pazopanib affects DC differentiation by inhibiting p-Erk/ b-catenin 
signaling. 
The Wnt-b-catenin pathway, particularly in DCs, regulates the balance 
between tolerance and immune response (Swafford D, Discov Med 2015). 
Loss of b-catenin impairs the ability of DCs to induce Tregs (Hong Y, 
Cancer Res 2015), instead the activation of b-catenin pathway increases 
the capacity of DC to release IL10 and promote immune tolerance, 
(Manoharan I, J Immunol 2014; Shan MM, Science 2013). In DCs, b-
catenin signaling synergizes with other pathways, such as the Erk 
pathway, to induce anti-inflammatory cytokines and proliferation of 
Tregs. Erk1/2 signaling retards the phenotypic and functional maturation 
of monocyte-derived human DCs (Puig-Kroger A, Blood 2001). To 
evaluate whether changes in DC functional activity were due to signaling 
differences, we examined DC intracellular 
pathways. Untreated DCs or DCs differentiated in the presence of 
sunitinib or pazopanib were lysed and probed with anti–p-Erk 1/2, anti–b-
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catenin and anti–NF-kB by western blot. DCs treated with pazopanib 
expressed less p-Erk ½ than did DCs treated with sunitinib or untreated 
DCs. This downregulation associated with a significant reduction of b-
catenin expression (iDCs and sunitinib-iDCs vs. pazopanib- iDCs P < 0.05; 
mDCs vs. pazopanib-mDCs P < 0.05). In both pazopanib-iDCs and 
pazopanib-mDCs, p-Erk1,2 and b-catenin antibodies detected a weaker 
signal than in untreated DCs and DCs treated with sunitinib, suggesting 
that pazopanib iDCs, 5% for mDCs) or sunitinib-treated DCs (14% for 
iDC, 5,1% for mDCs). No effect was observed on T cells cultured could act 
through these pathways. We analyzed the activation of NF-kB, which is 
essential for DC development and survival and regulates DC maturation. 
Results indicated that NF-kB activation was similar in all iDCs tested. 
Although the p50 signal was weaker in mDCs treated with pazopanib, the 
balance between all intracellular pathways favored the activation 
pathway. 
Modulation of DCs generated from mRCC patients treated with 
pazopanib or sunitinib. 
To confirm the pazopanib immune-priming effect in patients, we analyzed 
monocyte-derived DCs differentiated from mRCC patients during TKI 
treatment. DCs were differentiated in vitro by standard methodology 
without the addition of TKIs. Fig. 5 reported in published article shows 
the phenotype of DCs generated from PBMCs of RCC patients after one 
month of pazopanib or sunitinib treatment. CD14, a marker of DC 
immaturity, was less expressed in iDCs from patients treated with 
pazopanib (P < 0.01) than patients treated with sunitinib confirming data 
obtained in vitro. Moreover, DCs (both iDCs and mDCs) from 
pazopanibtreated patients expressed more of the activation markers 
HLADR and CCR7 and less PD-L1 (mDCs; P < 0.01) as compared with 
DCs generated from sunitinib-treated patients. For one patient, we 
evaluated the modulation of some DC markers differentiated before (T0) 
and during pazopanib therapy (T1: after 1 month of treatment, T2: after 2 
months) and results are shown in Supplementary Fig. S3A reported in 
published article. As with DCs generated in vitro with pazopanib, iDCs 
from this mRCC patient in treatment with pazopanib showed increased 
expression of HLA-DR at T2 and CD40 at T1 and T2. Expression of the 
coinhibitory molecule PD-L1 decreased during pazopanib treatment, both 
in iDCs and mDCs, confirming that pazopanib boosts DC activity. 
Immune profile of mRCC patients during TKI treatment. 
The priming of DCs by pazopanib could impact the immune repertoire in 
the peripheral blood ofmRCCpatients. To verify this hypothesis, we 
followed and monitored longitudinally mRCC patients undergoing TKI 
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therapy, either pazopanib or sunitinib. Patients had different previous 
therapies although all of the patients belonged to the same risk group. Six 
patients in treatment with TKIs for mRCC underwent peripheral blood 
sampling at different time points and PBMCs were isolated and analyzed 
by flow cytometer in order to investigate the evolution of patients' 
immunological profile during TKI administration. Patients 1, 2, and 3 
received pazopanib, whereas patients 4, 5, and 6 received sunitinib. The 
immunoassays were performed when possible at different time points. 
Two patients (patient 3 and 5) showed progressive disease and one of 
these died from the disease. The other four are still in treatment with TKIs. 
Several immunological parameters were evaluated for each patient at each 
time point considering the limited amount of blood sampling. In 
particular, we analyzed T-cell subpopulations, their activation status 
(CD137 expression), their proliferation ability as assessed by expression of 
Ki67, the immunosuppression as a percentage of Tregs, and T-cell 
exhaustion as assessed by expression of checkpoint inhibitors such as PD-
1, CTLA-4, and Tim-3. Pro- and anti-inflammatory cytokines were 
evaluated in serum of patients.  
We observed that pazopanib seemed to induce an increased number of 
CD3þCD137þ T cells (Fig. 6B). In patient 1, for example, activated 
(CD137þ) CD4þ T cells were 30% of the activated CD3þ T cells at time T2, 
compared with T0 (before pazopanib therapy, 0.3% of activated CD3þ T 
cells) and T1 (4.7% of CD3þ T cells). At T5, we observed a decrease of 
CD4þ and CD8þ CD137þ T-cell populations. In the same patient, plasma 
levels of IL6 dropped from T0 to T2, both IL4 and CXCL-10 increased at T1 
and T2, and ICAM decreased at T2. Ki67 expression, a proliferation signal 
for T cells, was higher at T2 than at other time points. Patient 2 had fewer 
CD137þ T cells from time T0 forward. Regulatory T cells decreased during 
treatment and Ki67þ T cells increased. Patient 3, who was monitored 
during pazopanib treatment and immediately after progression, showed 
enhancement of CD4þCD137þ T cells at T3 (54%) compared with T0 
(24.9%) and T1 (23.2%). This population decreased during progression 
under nivolumab treatment (T4, T5). This patient's Treg population was 
unchanged. PD1þ T cells increased slightly from T0 to T1, then decreased 
during pazopanib and nivolumab treatment. When we analyzed mRCC 
patients treated with sunitinib, we observed that CD137þ T cells were less 
evident, thus suggesting that this population could be influenced by the 
effect of pazopanib. In Patient 4, under sunitinib therapy, CD4þCD137þ T 
cells were barely detectable at all three time points. This patient presented 
with 29% of T cells being CD8þCD137þ T cells at T1; however, this 
population decreased to 14% at T2 and T3. In the same patient, the serum 
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concentrations of IL10 were increased at T2 compared with T1, whereas 
serum concentrations of IL12, IL4, and CXCL-10 decreased. In accordance 
with the increase of IL10, we observed an increase of Treg cells during 
sunitinib treatment, accompanied by upregulation of CTLA-4 expression 
on T cells at T3. Patient 5 showed a similar decreasing trend in CD137þ T-
cell population. Coinhibitory markers, such as CTLA-4 and Tim-3, 
increased during sunitinib treatment. Ki67þ T cells were decreased, and 
Treg cells were reduced. Patient 6 presented low and stable fractions of 
CD137þ T cells during sunitinib treatment when there time points were 
analyzed, although CD3þCD137þ T cells doubled at T7. At the same time 
IL10 and IL4 decreased compared with T5, and IL12 slightly increased. 








Endothelium is recognized as a major contributor in the efficacy of the 
immune response and several receptors are shared between participant 
cells. Research efforts have been directed in understanding the immune 
effects of anti angiogenic drugs. The interest is becoming urgent since with 
the possibility to introduce the ICIs during or combined with the anti 
angiogenic treatments in several cancers it is mandatory to consider these 
drugs from the point of view of their impact on the patient’s immune 
system. The important question is: can we use the normalization effect 
induced by the anti angiogenic drugs to potentiate immunotherapeutic 
strategies? Moreover how are the shared receptors among immune cells, 
i.e. VEGFR, influenced by the therapy? Can we use anti-angiogenetic 
drugs to turn a “cold” tumor into a “hot” one and prepare the cancer 
patient for a successful ICI therapy? 
The best readouts are the patients. Each of them has its own immune 
system, which has been shaped during life starting from host genetic 
factors and modulated in time by history of infectious diseases, 
environmental and lifestyle factors, stress and microbioma repertoire 
[Routy B, Science 2018). When the patient arrives to our attention with a 
diagnosed cancer, we need to consider not only the nature (histotype, 
genomic portrait, etc.) of the malignancy but also the immunological 
“fitness” of the patient, particularly at the tumor level. This is a novel 
approach and the new immunotherapy drugs require this information. In 
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this context our experiments on monocyte derived DCs (Zizzari IG, 
Cancer Immun Res 2018) indicated that plasmatic concentration of 
pazopanib were able to improve DC differentiation and performance, by 
upregulating maturation markers, dowregulating co-inhibitors molecules 
such as PD-L1 and increasing allogenic response and Th1 cytokine 
production. We demonstrated that the shut down of β-catenin pathway 
was the mechanism involved. The activation of the β-catenin pathway has 
been shown to correlate with the absence of T cells from the 
microenvironment in metastatic melanoma and urothelial cancers. The 
targeting of the β-catenin pathway has therefore been suggested as an 
optimal strategy to reestablish lymphocyte trafficking within the tumor 
[Spranger S, Nature 2015]. 
In ovarian cancer setting, the clinical benefit of bevacizumab has not been 
completely justified from a biological point of view. In particular, its 
interaction with patients’ immune system is still not completely 
elucidated, although a strong rationale about the interplay between its 
ligand (VEGF) and the host’s immune response suppression has already 
been shown [Lapeyre-Prost A, International Review of Cell and 
Molecular Biology 2017]. In particular, three different mechanisms related 
to VEGF-mediated immunosuppression have been assessed so far: 
inhibition of dendritic cell maturation [Gabrilovich DI, Nat. Med. 1996; 
Gabrilovich D, Blood 1998; Oyama T, J. Immunol. 1998) reduction of T 
cell tumor infiltration [Li B, Clin. Cancer. Res. 2006) and promotion of 
inhibitory cells in the tumor microenvironment [Facciabene A, Nature 
2011]. In this scenario, our study published on JCM (Napoletano C & 
Ruscito I, J Clin Med 2019) adds new evidence to the body of knowledge 
concerning the immune effects of bevacizumab in advanced cancer 
patients by showing that (1) ovarian cancer patients not treated with 
bevacizumab-based chemotherapy seem to have a more 
immunosuppressive profile with the presence of a rTreg population that 
persists until the end of III cycles of therapy; (2) patients that clinically 
respond to bevacizumab treatment show a discrete population of effector 
T cells at the beginning of therapy that is maintained throughout the 
treatment; (3) Tregs are mainly represented by non-suppressive regulatory 
T cells in clinically responding bevacizumab patients compared with 
nonresponding patients and are also stably maintained in this ratio (nsT 
reg > sup T reg) throughout the treatment; (4) after three cycles of 
treatment, nonresponding bevacizumab patients produce more 
immunosuppressive IL-10 cytokine compared with responding patients. 
It should be pointed out that these results were obtained by comparing 
two groups of patients that were matched for all clinical characteristics. 
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Particularly important is to notice that the performance status was similar 
among the two groups; this variable has been significantly associated with 
the immunological effects and response to several therapies [24]. 
Our results (Napoletano C & Ruscito I, J Clin Med 2019) also follow and 
confirm the original observation by our group [6] in which a significant 
reduction of Tregs and an increase in the proportion and function of 
effector CD8 T cells were found in an end-of-life ovarian cancer patient 
treated with low-dose intraperitoneal bevacizumab for malignant ascites. 
We also showed that responding bevacizumab-treated patients reported a 
higher percentage of circulating CD4 effector T cells compared with 
nonresponding bevacizumab patients, confirming what has already been 
observed in metastatic colorectal cancer [Manzoni M, Oncology 2010]. 
This data has key implications in the current panorama of oncological 
clinical approach. Indeed, it is reasonable to suggest that the circulating 
effector T cells recruited and sustained by bevacizumab treatment, thanks 
to its ability to restore tumor microvascular normalization [Goel S, 
Physiol. Rev. 2011], could be expanded by the administration of 
checkpoint inhibitor agents, thus giving a strong biological rationale for 
the combination of immunotherapy with bevacizumab antiangiogenetic 
therapy. In support of this consideration, tumor tissue derived from 
metastatic renal cell carcinoma (mRCC) patients treated with anti-PD-L1 
atezolizumab plus bevacizumab was recently found to show an increase 
in intratumoral CD8 T cells as well as an increase in intratumoral MHC-I, 
Th1 and T-effector markers, and chemokines. Trafficking lymphocytes 
also increased in tumors following bevacizumab and combination 
treatment [Wallin JJ, Nat. Commun. 2016]. 
Another interesting results of our studies who deserve a special discussion 
in this context is that in Ruscito I, Br J Cancer 2018 article, we observed 
that VEGFA overexpression in pOC has been most frequently found 
among patients with a cancer somatic mutation of BRCA1/2 genes. This 
finding is in line with two other previously published papers. In 2013, 
Danza (Danza, K. Eur. J. Hum. Genet. 2013) observed that BRCA-mutated 
breast cancer patients reported higher levels of VEGF mRNA (P = 0.04) 
compared with those without BRCA mutations. In 2016, another study 
revealed that a VEGF-dependent gene signature (VDGs) was 
overexpressed in OC BRCA mutation carriers (Yin X, Sci. Rep. 2016). An 
interesting hypothesis explaining the linking between BRCA1 mutation 
and VEGF overexpression in HGSOC has been recently proposed: in 2015 
Desai A and Colleagues (Desai A, J Gynecol Res 2015) pointed out that 
wild-type BRCA1 binds to Ubc9, which induces Caveolin-1 expression, 
downregulates VEGF and regulates endothelial function in normal ovaries 
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and fallopian tubes. In HGSOC with BRCA1 dysfunction, Ubc9 is not 
binded and this inhibits Caveolin-1 expression causing increased VEGF 
levels, loss of endothelial function and accumulation of ascites. Compared 
to these previous studies, we also confirmed in our cohort the positive 
influence of BRCA mutations on OC patients’ survival (Yang D, JAMA 
2011; Bolton, K. L., JAMA 2012), as well as the significant association 
between BRCA mutation and VEGF-positivity determined VEGFpositivity 
a good prognostic factor in our HGSOC series. This result may also reflect 
the highly selection of the sample analysed, which only included HGSOC 
patients, who can also undergo secondary cytoreductive surgery for 
recurrence. These patients have usually good performance status and low 
tumour burden, so there is a selection of patients with a better clinical 
outcome (Norquist BM, Clin. Cancer Res. 2018). Furthermore, patients 
have been treated in high volume centres, with high experience in surgical 
treatment of ovarian cancer. 
In conclusion, these studies sheds a light on the strong need to routinely 
include immunomonitoring in ovarian cancer clinical protocols of patients 
during the course of antiangiogenetic therapy administrations, with the 
final aim being to identify early the subset of patients who can mostly 
benefit from its adoption. Furthermore, our studies provides a first 
rationale regarding the positive immunologic impact of combining 
bevacizumab with checkpoint inhibitors.  
In light of this evidence, results of the following ongoing phase III trials 
exploring combination of ICIs and PARPIs and/or anti-VEGF drugs are 
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Characterisation of tumour microvessel density during
progression of high-grade serous ovarian cancer: clinico-
pathological impact (an OCTIPS Consortium study).
Ilary Ruscito1,2, Dan Cacsire Castillo-Tong3, Ignace Vergote4, Iulia Ignat1, Mandy Stanske5, Adriaan Vanderstichele4, Jacek Glajzer1,
Hagen Kulbe1, Fabian Trillsch6,7, Alexander Mustea8, Caroline Kreuzinger3, Pierluigi Benedetti Panici9, Charlie Gourley10,
Hani Gabra11,12, Marianna Nuti2, Eliane T. Taube5, Mirjana Kessler13, Jalid Sehouli1, Silvia Darb-Esfahani5 and Elena Ioana Braicu1
BACKGROUND: High-grade serous ovarian cancer (HGSOC) intratumoural vasculature evolution remains unknown. The study
investigated changes in tumour microvessel density (MVD) in a large cohort of paired primary and recurrent HGSOC tissue samples
and its impact on patients’ clinico-pathological outcome.
METHODS: A total of 222 primary (pOC) and recurrent (rOC) intra-patient paired HGSOC were assessed for immunohistochemical
expression of angiogenesis-associated biomarkers (CD31, to evaluate MVD, and VEGF-A). Expression profiles were compared
between pOCs and rOCs and correlated with patients' data.
RESULTS: High intratumoural MVD and VEGF-A expression were observed in 75.7% (84/111) and 20.7% (23/111) pOCs, respectively.
MVDhigh and VEGF(+) samples were detected in 51.4% (57/111) and 20.7% (23/111) rOCs, respectively. MVDhigh/VEGF(+) co-
expression was found in 19.8% (22/111) and 8.1% (9/111) of pOCs and rOCs, respectively (p= 0.02). Pairwise analysis showed no
significant change in MVD (p= 0.935) and VEGF-A (p= 0.121) levels from pOCs to rOCs. MVDhigh pOCs were associated with higher
CD3(+) (p= 0.029) and CD8(+) (p= 0.013) intratumoural effector TILs, while VEGF(+) samples were most frequently encountered
among BRCA-mutated tumours (p= 0.019). Multivariate analysis showed VEGF and MVD were not independent prognostic factors
for OS.
CONCLUSIONS: HGSOC intratumoural vasculature did not undergo significant changes during disease progression. High
concentration of CD31(+) vessels seems to promote recruitment of effector TILs. The study also provides preliminary evidence of the
correlation between VEGF-positivity and BRCA status.
British Journal of Cancer (2018) 119:330–338; https://doi.org/10.1038/s41416-018-0157-z
INTRODUCTION
High-grade serous ovarian carcinoma (HGSOC) still accounts for
the highest mortality rate among all ovarian cancer (OC)
histotypes, with almost 80% of all new deaths from OC being
caused by this distinct subgroup of ovarian tumours.1–4 Interna-
tional groups of opinion leaders have recognised the designing of
new translational studies on recurrent and end-stage HGS tumour
tissue samples as a key 'unmet need' in the understanding of
HGSOC biology and clonal evolution.4
In this scenario, analysis of the evolution process affecting
intratumoural vasculature during HGSOC progression is a pivotal
issue to be still elucidated.
After decades of paralysis in primary OC first-line chemotherapy
treatment, indeed, incorporation of bevacizumab in the upfront
regimen for advanced newly diagnosed disease5 has changed the
'standard of care paradigm' of advanced primary OC, although
characterised by less survival impact than expected.6–8 Thus,
understanding changes in the vasculature or identification of
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prognostic biomarkers of response to vasculature targeting is
needed. Unfortunately, there are currently no predictive biomar-
kers to tailor bevacizumab treatment in OC patients.
A full knowledge of molecular changes involving intratumoural
vasculature from primary to recurrent HGSOC is still lacking and
may provide new opportunities to: (1) tailor treatment with
currently available anti-angiogenetic agents, (2) shed light on
acquired resistance mechanisms, and (3) develop new targeted
therapies.
The aim of this study was to identify changes occurring from
primary to recurrent HGSOC in tumour tissue expression of the
angiogenesis-associated biomarkers CD31, applied for detecting
microvessels density (MVD),9–11 and VEGF-A,12 by analysing a large
cohort of paired primary and recurrent HGSOC tissue samples.
Secondary endpoints included the correlation of biomarkers




Paired cancer tissue samples belonging to HGSOC patients were
collected during primary and secondary cytoreduction. Patients
were treated with primary debulking surgery followed by
platinum-based chemotherapy between 1985 and 2013, and were
retrospectively and consecutively selected from OCTIPS (Ovarian
Cancer Therapy–Innovative Models Prolong Survival, Agreement
No.279113-2) Consortium database. Included patients underwent
both primary (pOC) and recurrent (rOC) surgery in one of the
European Gynaecologic Oncology referral Centers of the following
Institutions: Charité Universitätsmedizin Berlin, Germany; Catholic
University of Leuven, Belgium; Imperial College, London, UK;
University of Edinburgh, UK; University Medical Center Hamburg-
Eppendorf, Germany.
Inclusion criteria were: availability of paired primary and
recurrent cancer tissue samples from HGSOC patient together
with clinical annotation. Exclusion criterion was: neoadjuvant
chemotherapy treatment, due to the need to analyse primary
chemo-naïve tumours. Approval from each local ethics committee
was obtained (EK207/2003, ML2524, 05/Q0406/178, EK130113, 06/
S1101/16). All included samples underwent central histopatholo-
gical assessment to confirm HGSOC histology and ensure tumour
tissue content and quality.
Immunohistochemistry
Tissue microarrays (TMA) were constructed for immunohisto-
chemical staining. Each primary and recurrent tumour tissue
sample was represented within the TMA by two tumour cores,
each containing at least 90% of cancer cells.
Sections from TMA were deparaffinised in xylol, rehydrated in
graded alcohol, and boiled in pressure cooker for 5 minutes in
citrate buffer (pH= 6), for CD31 staining, or in EDTA (pH= 9), for
VEGF staining. Rabbit anti-human CD31 antibody (clone ab32457;
Abcam, Cambridge, MA, USA) and rabbit anti-human VEGF-A
antibody (clone A-20; Santa Cruz Biotechnology, Dallas, TX, USA)
were diluted 1:20 and 1:250, respectively, and incubated on slides
for 60minutes at room temperature. Bound antibodies were
visualised using DAKO Real Detection System and DAB+ (3,3′-
diaminobenzidine; DAKO, Glostrup,Denmark) as a chromogen.
Finally, the slides were co-stained with hematoxylin.
CD31 stained samples were assessed in terms of MVD. MVD was
determined by averaging the number of vessels from three
distinct areas of tumour with highest vessels density examined at
×200 magnification.13–15
Samples were further classified into 'MVDhigh' (≥16.3 vessels) or
'MVDlow' (<16.3 vessels), establishing the cut-off level of MVD
count for dichotomisation at first quartile (primary samples), being
the value able to maximise difference in OS hazard ratio13,15,16
(Table S1).
For VEGF staining evaluation, the number of stained tumour
cells within the whole TMA cores (0%= 0; 1–10%= 1; 11–50%=
2; >50%= 3) was multiplied with the intensity of staining
(negative= 0; weak= 1; moderate= 2; strong= 3),17 resulting in
a semiquantitive immunoreactivity score (IRS) ranging from 0 to 9.
Samples were classified as 'VEGF(+)', for VEGF-high tumour
expression (IRS= 4–9), or as 'VEGF(−)', for absent/weak focal
staining (IRS= 0–3).
As positive control for IHC were used human liver sections.
Samples staining was assessed independently by two co-authors
(IR and SDE).
Patients’ clinico-pathological data
Patients’ clinico-pathological data, including somatic-BRCA status
from 52 included patients, were retrieved from OCTIPS Con-
sortium database.18 GCIG criteria were applied to define platinum-
resistance and platinum-sensitivity.19 RECIST Criteria were applied
during patients’ follow-up to define HGSOC relapse.20 No residual
tumour was defined intraoperatively by the surgeon in case no
macroscopic tumour could be detected at the end of
cytoreduction.
Table 1. Patient characteristics
Patients n 111
Age






Residual tumour after PDS:
No Residual Tumour 89 (80.2%)
Any Residual Tumour 22 (19.8%)
Type of first-line CHT
With bevacizumab 2 (1.8%)
Without bevacizumab 109 (98.2%)
Type of second-line CHT
With bevacizumab 8 (7.2%)
Without bevacizumab 103 (92.8%)
Platinum response after primary treatment
Platinum sensitive 90 (81.1%)
Platinum resistant 18 (16.2%)
Unknown 3 (2.7%)
Platinum response after treatment for disease relapse
Platinum sensitive 59 (53.2%)
Platinum resistant 12 (10.8%)
Missing 40 (36%)
Somatic-BRCA status
BRCA wt 31 (27.9%)
BRCA 1/2 mutation 21 (18.9%)
Unknown 59 (53.2%)
Maximum follow-up time 214 months
Median OS 63 months
CHT Chemotherapy, OS Overall survival, PDS Primary debulking surgery, wt
wild type
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In order to investigate any association between different
tumour vasculature profiles and intratumoural immune infiltrate
in both pOCs and rOCs, MVD and/or VEGF profiles were matched
with previous OCTIPS data on tumour infiltrating lymphocytes
(TILs), assessed through the immunohistochemical expression of
CD3, CD4, and CD8 biomarkers, as previously reported.21
Furthermore, immunosuppressive TILs were evaluated through





























































































Fig. 1 CD31 immunohistochemistry staining for intratumoural MVD assessment: MVDhigh (a) and MVDlow (b) pOC samples; MVDhigh (c) and
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Fig. 2 VEGF-A immunohistochemistry staining. VEGF-A IRS distribution in primary (a) and recurrent (d) tumour samples. pOCs, VEGF(+) (b) and
VEGF(−) (c); rOCs, VEGF(+) (e) and VEGF(−) (f); VEGF-A IRS among primary and recurrent tumours (box plot (g) and scatter plot (h))
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using the mouse anti-human FOXP3 antibody (clone ab20034;
Abcam, Cambridge, MA, USA, 1:200, 1.5 h at room temperature).
The count of stained FoxP3-positive TILs was then performed
automatically with the VM Scope Quantifier, as previously
reported.21
Statistical Analysis
Statistical analysis was performed using SPSS version 22.0 (SPSS
Inc,Chicago,IL,USA). Difference in biomarker expression between
pOCs and rOCs was assessed through the correlation test
(Spearman coefficient, 2-tailed) and 'Wilcoxon signed rank' non-
parametric test for related samples. Fisher’s exact test was applied
to correlate MVD and/or VEGF tumour expression with patients’
clinico-pathological categorical data. Patients’ progression-free
interval (PFI), progression-free survival (PFS), and overall survival
(OS) were identified through Kaplan–Meier analysis (Log-Rank
test). PFI was defined as the time interval from the last adjuvant
chemotherapy to relapse, whereas progression-free survival (PFS)
was established as the time interval between first recurrence
diagnosis and tumour progression. Univariate and multivariate
survival analyses were performed applying Cox-regression model.
Multivariable models were obtained among variables reporting a
p-value ≤ 0.1 in univariate analysis. p-values ≤ 0.05 were evaluated
statistically significant.
RESULTS
A total of 222 intra-patient paired primary and recurrent HGSOC
tissue samples derived from 111 patients were included. Patients’
characteristics are listed in Table 1. To note, only 2/111 (1.8%)
patients received bevacizumab in front-line chemotherapy, thus
the staining of recurrent samples have not been influenced by
first-line administration of anti-angiogenetic compounds.
MVD staining
MVDhigh staining was detected in 75.7% (84/111) of pOC and in
51.4% (57/111) of rOC, whereas MVDlow staining was found in
24.3% (27/111) and in 48.6% (54/111) of pOC and rOC,
respectively. MVDlow staining was twice as prevalent in relapsed
tumours compared to primary disease (p= 0.0003, Fisher’s exact
test, Fig. 1a–d). Nevertheless, globally, pairwise analysis revealed
no tendency towards a change in MVD to higher or lower levels in
recurrent samples (p= 0.935, Wilcoxon test; Fig. 1e), as well as no
significant correlation between pOCs and rOCs in MVD was
reported (Spearman correlation, p= 0.920; Spearman coefficient:
0.01).
VEGF-A expression
VEGF IRS distribution in both pOCs and rOCs is shown in Fig. 2a, d.
The same percentage of VEGF(+) (20.7%, 23/111) and VEGF(−)
(79.3%, 88/111) tumour samples was found between pOCs and
rOCs, respectively, (p= 1, Fisher’s exact test, Fig. 2b, c, e, f),
although no significant correlation between pOCs and rOCs VEGF
IRS values could be observed (p= 0.505, Spearman coefficient
0.06). Furthermore, pairwise analysis confirmed no tendency
towards a change in VEGF IRS levels at tumour relapse (p=
0.121, Wilcoxon test; Fig. 2g).
MVDhigh and VEGF(+) co-expression in pOCs vs rOCs.
MVDhigh and VEGF(+) co-expression was more frequent in pOCs
group (22/111, 19.8%) compared to rOCs (9/111, 8.1%) (p= 0.02,
Fisher’s exact test, Fig. S1).
Relationship between MVD and/or VEGF-A expression with TILs.
Results showed that MVDhigh levels in pOCs samples were
associated with higher CD3(+) (p= 0.029, Mann–Whitney test)
and CD8(+) (p= 0.013) effector TILs, but not with a higher FoxP3(+)
(p= 0.443) T-regulatory cells infiltrate. To note, the correlation
between MVD and CD3(+)/CD8(+) TILs disappeared at tumour
recurrence. No significance between pOCs or rOCs VEGF expres-
sion or MVDhigh+ VEGF(+) co-staining with TILs was reported
(Fig. S2, Table S2).
MVD and/or VEGF-A profiles and patients’ clinico-pathological
factors
Analysis on the correlation between MVD and/or VEGF expression
in pOCs with patients’ clinico-pathological characteristics is shown
in Table 2. In particular, VEGF(+) primary HGSOCs and MVDhigh/
VEGF(+) primary samples were most frequently encountered
among somatic-BRCA-mutated tumours compared to somatic-
BRCA wild-type cases (p= 0.019, Fisher’s exact test). No further
significant associations between different intratumoural
Table 2. Association of MVD and/or VEGF expression with patients’ clinico-pathological characteristics (pOCs)
Clinico-pathological factors Total N MVD (pOC) VEGF (pOC) MVD high+ VEGF pos co-
expression (pOC)
High Low P High Low P Yes No P
Patients’ Age
<56 y 53 39 14 0.663 13 40 0.360 13 40 0.246
≥56 y 58 45 13 10 48 9 49
FIGO Stage
I/II 7 4 3 0.358 2 5 0.633 2 5 0.624
III/IV 104 80 24 21 83 20 84
Residual tumour after first cytoreductive surgery
No residual 89 67 22 1 18 71 0.775 17 72 0.767
Any residual 22 17 5 5 17 5 17
Platinum-sensitivity status after primary treatment
Platinum sensitive 90 71 19 0.133 18 72 0.530 17 73 0.521
Platinum resistant 18 11 7 5 13 5 13
Somatic-BRCA status
BRCA-WT 31 26 5 0.105 3 28 0.019 3 28 0.019
mBRCA1/2 21 13 8 8 13 8 13
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vasculature profiles and patients’ age at diagnosis, FIGO stage,
residual tumour after primary debulking or first-line platinum
response was identified.
Decrease of VEGF expression in rOCs was observed only in
BRCA-mutated patients (p= 0.053, Wilcoxon test), although this
association did not reach statistical significance (Fig. S3).
Survival
Patients, whose pOCs resulted MVDhigh, VEGF(+) or co-stained for
both biomarkers, were found to have a significantly improved OS
compared to patients without these intratumoural profiles at
primary disease (Fig. 3g–i). In particular, median OS for MVDhigh
and MVDlow patients was 67 and 46 months, respectively (p=
0.019), median OS for VEGF(+) and VEGF(−) patients resulted 76 vs
52 months, respectively (p= 0.036), while median OS for patients
with co-stained pOCs was 76 months, compared to 52 months in
women without co-expression (p= 0.021).
On the contrary, no influence of pOCs or rOCs MVD and/or VEGF
expression on patients’ time to progression after primary (PFI) or
first recurrent disease (PFS) was reported (Fig. 3a–f).
Multivariate analysis for OS and PFI was carried out on the
whole patients’ population (n= 111) and also on the subgroup of
patients (n= 52) with known tumour somatic-BRCA status.
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Fig. 3 MVD and/or VEGF status and progression-free survival after primary (PFI (a), (b), (c)) and recurrent (PFS, (d), (e), (f)) disease. g–i MVD
and/or VEGF status at primary disease and overall survival. 'x-axis': months, 'y-axis': survival probability
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Table 3. Multivariate analysis for OS
HR (95% CI) P
a: Whole population (n= 111)
Overall survival
Age (≥56 y vs <56 y) 1.155 (0.683–1.953) 0.590
FIGO stage (III/IV vs I/II) 2.507 (0.621–10.127) 0.197
Residual tumour (any residual vs no residual) 1.610 (0.875–2.962) 0.126
MVD (high vs low) 0.818 (0.417–1.604) 0.558
VEGF (positive vs negative) 0.420 (0.178–0.991) 0.048
FoxP3 mean number 0.963 (0.778–1.191) 0.727
CD3 mean number 1.000 (0.998–1.002) 0.786
CD4 mean number 1.000 (0.999–1.001) 0.925
CD8 mean number 1.000 (0.998–1.002) 0.846
Platinum response (Plat. Sens. vs Plat. Resist) 0.229 (0.104–0.506) < 0.001
b: Only somatic-BRCA-tested population (n= 52)
Overall survival
Age (≥56 y vs <56 y) 1.017 (0.410–2.524) 0.971
FIGO stage (III/IV vs I/II) 1.506 (0.091–24.829) 0.775
Residual tumour (any residual vs no residual) 1.417 (0.259–7.755) 0.687
MVD (high vs low) 0.747 (0.243–2.291) 0.609
VEGF (positive vs negative) 0.440 (0.127–1.526) 0.196
FoxP3 mean number 0.683 (0.439–1.061) 0.090
CD3 mean number 0.998 (0.994–1.001) 0.132
CD4 mean number 0.997 (0.995–1.000) 0.038
CD8 mean number 0.998 (0.994–0.997) 0.438
Somatic-BRCA status (BRCA–mut vs BRCA wt) 0.354 (0.133–0.994) 0.038
Platinum response (Plat. Sens. vs Plat. Resist) 0.216 (0.051–0.991) 0.037
c: Whole population (n= 111)
Progression-free interval
Age (≥56 y vs <56 y) 1.067 (0.692–1.644) 0.770
FIGO stage (III/IV vs I/II) 2.447 (0.892–6.711) 0.082
Residual tumour (any residual vs no residual) 1.009 (0.568–1.794) 0.974
MVD (high vs low) 1.445 (0.832–2.511) 0.191
VEGF (positive vs negative) 0.945 (0.541–1.652) 0.843
FoxP3 mean number 0.984 (0.832–1.162) 0.845
CD3 mean number 1.000 (0.999–1.001) 0.835
CD4 mean number 1.000 (0.999–1.001) 0.698
CD8 mean number 1.000 (0.998–1.002) 0.845
d: Only somatic-BRCA-tested population (n= 52)
Progression-free interval
Age ( ≥ 56 y vs < 56 y) 1.121 (0.542–2.318) 0.759
FIGO stage (III/IV vs I/II) 18.261 (1.282–260.172) 0.032
Residual tumour (any residual vs no residual) 1.391 (0.280–6.918) 0.687
MVD (high vs low) 0.884 (0.375–2.081) 0.777
VEGF (positive vs negative) 0.916 (0.400–2.095) 0.834
FoxP3 mean number 0.868 (0.659–1.145) 0.317
CD3 mean number 0.998 (0.995–1.001) 0.159
CD4 mean number 0.996 (0.993–0.998) 0.001
CD8 mean number 0.999 (0.995–1.003) 0.719
Somatic-BRCA status (BRCA-mut vs BRCA wt) 0.982 (0.462–2.087) 0.962
Multivariate analysis for OS carried out on (a) the whole patients’ population (n= 111), (b) only somatic-BRCA-tested population (n= 52) and multivariate analysis
for PFI carried out on (c) the whole patients’ population (n= 111), (d) only somatic-BRCA-tested population (n= 52). Bold values indicate significant p values (<0.05)
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independent prognostic factor for OS anymore when considering
also somatic-BRCA mutational status. Only somatic-BRCA mutation
(HR: 0.354, CI 95%: 0.133–0.994; p= 0.038), high CD4(+) TILs (HR:
0.997, CI 95%: 0.995–1.000; p= 0.038) and first-line platinum
response (HR: 0.216, CI 95%: 0.051–0.991; p= 0.037) were found to
independently improve HGSOC patients’ OS.
When analysing the PFI in patients with or without BRCA
somatic mutations, advanced FIGO stage (HR: 18.261, CI 95%:
1.28–260.17; p= 0.032) and low CD4(+) TILs (HR: 0.996, CI 95%:
0.993–0.998; p= 0.001) were the only independent poor prog-
nostic factors (Table 3c, d).
DISCUSSION
In the last decade, 'omics' sciences provided fundamental insight
into the understanding of HGSOC biology,3 showing as one
distinct malignancy with its own characteristic phenotype,
aetiology and progression profile.22 Although known for its
aggressive behaviour, HGSOC has a higher change to show
durable response after first-line chemotherapy, compared to other
OC histologies,23 as well as its common platinum-sensitivity allows
it to access a more varied panel of experimental second-line
combinations.24 Unfortunately, progression from HGSOC is often
rapid and chemo-resistance develops.4
In this context, understanding the biological changes occurring
to HGSOC during disease progression is an essential issue through
which new identified biomolecular signatures, marking the
HGSOC clinical evolution, could help developing new tailored
treatment strategies.
In this study, OCTIPS Consortium aimed to identify modifica-
tions involving HGSOC intratumoural vasculature from primary to
recurrent disease, by assessing the evolution of cancer MVD and
VEGF-A expression. Results showed that: (1) MVD and/or VEGF
levels did not undergo significant changes from pOC to rOC
(being in line with already available clinical findings, as
bevacizumab is showing mild improvement in PFS, in both
primary and relapsed situation);5,7,8 (2) High MVD levels in pOC
seems to sustain the intratumoural recruitment of effector TILs
and were associated with better OS in HGSOC patients; (3) VEGF(+)
HGSOCs were most frequently encountered among somatic-
BRCA-mutated tumours and VEGF-positivity correlates with better
OS in this HGSOC cohort; (4) MVD and VEGF were not
independent prognostic factor for OS when taking into account
the BRCA mutational status and TILs profile.
The definition of 'intratumoural microvessel density' has been
coined in the middle of 90’s to objectivise the entity of blood
supply available within the tumour mass to sustain cancer
growth.25 Intratumoural vessels are usually characterised by
impaired vascular maturation, poor functionality and defects in
endothelial architecture. Immaturity of the new generated
tumour-associated vasculature results in excessive permeability,
poor perfusion and imperfect blood flow.26
During the last 20 years, different studies recognised 'high' MVD
a poor prognostic factor for cancer patients,27–29 including women
affected by OC.30 Different biomarkers have been adopted to
assess MVD in OC, including Von Willebrand Factor, CD105, CD34
and CD31, being CD34 the most used MVD detector and the
biomarker associated with the poorest HR for OS (HR: 1.67, CI 95%:
1.36–2.35) compared to other MVD detectors (HR: 1.32, CI 95%:
0.82–1.82).30
CD31, also known as 'platelet endothelial cell adhesion
molecule-1' (PECAM-1) is a transmembrane glycoprotein
expressed on endothelial cells, platelets, neutrophils and T-
cells. It is a key factor to maintain the integrity of endothelial
cells permeability barrier and to promote the controlled
activation of T-cells and their survival,11,31,32 thus being
expression of a normalised endothelium able to sustain the
correct trafficking of T-cells into the tumour. In line with CD31
biological role, we observed that MVDhigh levels in pOCs
samples correlated with higher CD3(+) and CD8(+) TILs, but
not with a higher FoxP3(+) T-lymphocytes infiltrate, thus
suggesting that a high concentration of intratumoural CD31(+)
vessels might be able to promote the intratumoural recruitment
of effector T-cell populations, thus ultimately improving
patients’ survival.33 Recently, Bais et al.16 identified CD31-
dependent MVD as a predictive biomarker for bevacizumab
response in first-line treated OC patients. This finding might be
consequence of intratumoural endothelial maturity, represented
by high CD31-dependent MVD levels, able to ensure a normal-
ised blood flow, which is pivotal for intratumoural drug delivery
and efficacy.26
Vascular Endothelial Growth Factor (VEGF) is a key angiogenetic
cytokine that regulates cell mitosis and endothelial cells perme-
ability.34 Overexpression of VEGF has been found to correlate with
cancer relapse and decreased survival in patients affected by
different solid tumours, including OC.35 Despite previous studies,
absence of significant changes in MVD and VEGF profile following
disease progression of this unique cohort, indicates that these
markers are not major drivers of molecular cancer evolution
in vivo, but rather remain supportive factors.
One of the most intriguing outcomes of our study is that VEGF-
A overexpression in pOC has been most frequently found among
patients with a cancer somatic mutation of BRCA1/2 genes. This
finding is in line with two other previously published papers. In
2013, Danza36 observed that BRCA-mutated breast cancer patients
reported higher levels of VEGF mRNA (P= 0.04) compared with
those without BRCA mutations. In 2016, another study revealed
that a VEGF-dependent gene signature (VDGs) was overexpressed
in OC BRCA mutation carriers.37 An interesting hypothesis
explaining the linking between BRCA1 mutation and VEGF
overexpression in HGSOC has been recently proposed: in 2015
Desai A and Colleagues38 pointed out that wild-type BRCA1 binds
to Ubc9, which induces Caveolin-1 expression, downregulates
VEGF and regulates endothelial function in normal ovaries and
fallopian tubes. In HGSOC with BRCA1 dysfunction, Ubc9 is not
binded and this inhibits Caveolin-1 expression causing increased
VEGF levels, loss of endothelial function and accumulation of
ascites. Compared to these previous studies, we also confirmed in
our cohort the positive influence of BRCA mutations on OC
patients’ survival,39,40 as well as the significant association
between BRCA mutation and VEGF-positivity determined VEGF-
positivity a good prognostic factor in our HGSOC series. This result
may also reflect the highly selection of the sample analysed, which
only included HGSOC patients, who can also undergo secondary
cytoreductive surgery for recurrence. These patients have usually
good performance status and low tumour burden, so there is a
selection of patients with a better clinical outcome.41 Furthermore,
patients have been treated in high volume centres, with high
experience in surgical treatment of ovarian cancer. Most Centers
have been also approved and allowed to participate in the LION
(ClinicalTrials.gov Identifier: NCT00712218), DESKTOP III (Clinical-
Trials.gov Identifier: NCT01166737) and TRUST (ClinicalTrials.gov
Identifier: NCT02828618) studies, based on the high quality of the
tumour debulking.
Nevertheless, further studies aiming to assess the association
between BRCA mutation and VEGF overexpression would provide
new instrument to personalise treatment with anti-angiogenetic
agents among BRCA-mutated and BRCA wild-type OC patients.42
In this scenario, the randomised phase III clinical trial ENGOT-ov25/
PAOLA-1 (ClinicalTrials.gov Identifier: NCT02477644), which com-
bines in advanced OC patients bevacizumab-based first-line
treatment with or without the PARP-Inhibitor olaparib, could be
able to add evidence concerning functional impact of VEGF
expression in tumours with impaired homologous DNA repair
mechanism.
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To our knowledge, this is the first study analysing the changes
occurring in intratumoural vasculature during disease progression
in the largest cohort of paired primary and recurrent HGSOC
samples. It firstly demonstrated that the vascular architecture
within the tumour mass, in absence of anti-angiogenic agents
administration, is maintained relatively stable during the natural
course of the disease. Furthermore, the subanalysis on patients
with known somatic-BRCA status increases the value of findings
by taking into account the impact of BRCA status on patients’
survival39,40 and provides preliminary evidence of the correlation
between VEGF-positivity and BRCA mutation.
The main limitation of the study is its retrospective nature. One
of the strengths of this analysis is the large sample size of paired
primary and recurrent tumour tissue samples belonging to the
same cancer subtype (n= 222), the high quality of specimens and
the systematisation of multicentric patients’ clinico-pathological
data. Furthermore, inclusion of patients not subjected to the
bevacizumab-based first-line chemotherapy, increase the relia-
bility of the results in comparing intratumoural vasculature profiles
from primary to recurrent disease.
Future study on a larger population with known BRCA status,
who has been subjected to bevacizumab-based first-line che-
motherapy, is warranted to clarify the role of MVD and VEGF in
predicting bevacizumab response in both BRCA-wt and BRCA-
mutated HGSOC patients.
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Abstract: Increasing evidence strongly suggests that bevacizumab compound impacts the 
immunological signature of cancer patients and normalizes tumor vasculature. This study aims to 
investigate the correlation between the clinical response to bevacizumab-based chemotherapy and 
the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood 
mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively 
selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and 
Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were 
monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 
production. A lower activated and resting Treg subset was found in the Bev group compared with 
the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. 
Indeed, clinically responding patients in the Bev group showed a high percentage of non-
suppressive Treg and a significant lower IL10 production compared with non-responding patients 
in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete 
population of effector T cell at T0 independent of the therapeutic regimen. This subset was 
maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab 
could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining 
the circulation of the effector T cells. Results also provide a first rationale regarding the positive 
immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian 
cancer patients. 
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Ovarian cancer still accounts for the highest mortality rate among all gynecological malignancies, 
with 295,414 estimated new cases and 184,799 estimated new deaths in 2018 worldwide [1]. 
During the last 10 years, bevacizumab, a monoclonal antibody that binds to vascular endothelial 
growth factor (VEGF), has revolutionized the treatment approach in ovarian cancer, obtaining US Food 
and Drug Administration (FDA)/ European Medicines Agency (EMA) approval in all advanced disease 
settings (multi-treated/compassionate, platinum-resistant/platinum-sensitive recurrent, and primary 
International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IV ovarian cancer) 
(www.fda.gov; www.ema.europa.eu). 
The biological mechanism underpinning the clinical efficacy of bevacizumab addition in ovarian 
cancer setting is still a matter of intense investigation. Increasing evidence supports the hypothesis 
that this biological compound modulates patients’ immune system, reducing immunosuppression 
and activating acquired immunity [2]. Several authors have shown the immune effects of 
bevacizumab in multiple cancer settings, such as decrease in patients’ regulatory T cells (Tregs) [3,4] 
and expansion of B and T cells [2]. 
Multi-treated recurrent ovarian cancer patients constitute an extremely fragile disease setting. 
Their immune system is weakened by multiple lines/types of treatment strategies, and the succession 
of therapeutic choices for them is currently discussed without a common consensus among 
oncologists. 
In this study, we show that the clinical response to bevacizumab-based chemotherapy in this 
poor-prognostic disease correlates with improvement of patients’ immune fitness, thus providing 
new evidence that the benefit of such treatment can be ascribed also to its fine immune modulation. 
2. Experimental Section 
2.1. Patient Selection 
This retrospective study received institutional review board (IRB) approval and was carried out 
following the rules of the Declaration of Helsinki of 1975. Patients included in this study were treated 
at the Gynecologic Oncology Unit of the Department of Gynecology, Obstetrics and Urology 
(Sapienza University of Rome, Italy) between 2008 and 2012. Since 2007, all gynecological cancer 
patients admitted in this department have been regularly subjected to donation of peripheral blood 
samples every three cycles of chemotherapy treatment for research purposes with their written 
informed consent. Patients’ peripheral blood mononuclear cells (PBMCs) were regularly collected 
and stored in liquid nitrogen at the Laboratory of Tumor Immunology and Cell Therapy Unit, 
Department of Experimental Medicine (Sapienza University of Rome, Italy—Ethical Committee 
approval, protocol n° 703/2008; date of approval 07/24/2008).  
For this study, 20 consecutive recurrent ovarian cancer patients were retrospectively selected 
from “Sapienza” PBMC sample collection. All available multi-treated platinum-resistant ovarian 
cancer patients subjected to intraperitoneal (i.p.) bevacizumab-based chemotherapy as 
compassionate use were selected (Bev group; 10 patients), together with 10 patients (Ctrl group) that 
received non-bevacizumab-based chemotherapy.  
Inclusion criteria were as follows: primary diagnosis of advanced epithelial serous ovarian 
cancer; having been subjected to at least three previous chemotherapy lines; diagnosis of tumor 
progression confirmed by CT scan; presence of malignant ascites; life expectancy of at least three 
months; and availability of at least three PBMC samples per patient collected during the course of 
bevacizumab-based versus non-bevacizumab-based chemotherapy. Furthermore, patients of the Bev 
group were matched with the Ctrl group patients for age, tumor grading, FIGO stage, type of primary 
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treatment strategy (primary debulking surgery versus neoadjuvant chemotherapy followed by 
interval debulking surgery), tumor residual at first surgery, and type of recurrence at the time of 
blood sampling in order to minimize selection bias and avoid misinterpretations of results.  
Ten patients were identified as the ones that had received i.p. bevacizumab 5 mg/kg every 21 
days immediately after paracentesis for treatment of malignant ascites [5,6] plus intravenous 
(intravenous injection, i.v.) monochemotherapy (cisplatin) [7], while 10 other patients were identified 
as been treated with i.v. monochemotherapy alone (paclitaxel, topotecan, pegylated liposomal 
doxorubicin, cisplatin). Patients’ clinicopathological data were retrieved from clinical charts. Disease 
progression was defined basing on the response evaluation criteria in solid tumors (RECIST) [8]. 
2.2. PBMC Purification 
PBMCs were isolated from 12 to 14 mL of peripheral blood by Ficoll–Hypaque gradient (1077 g/mL; 
Pharmacia LKB, Sweden), obtaining a yield between 10 × 106 and 12 × 106 cells for each drawing and 
cryopreserved until use. Samples were taken before therapy (T0) and after three (III) and six (VI) 
cycles of therapy. 
2.3. Cell Phenotype 
Cell phenotype staining was performed using several directly conjugated monoclonal 
antibodies (MoAbs). T cells were incubated with the anti-CD8-PE-Cy5.5 (RPA-T8 clone), anti-CD3-
PE (UCHT1 clone), anti-CCR7-FITC (150503 clone), and anti-CD45RA-APC (HI100 clone) MoAbs, all 
from Becton Dickinson (Franklin Lakes, NJ, USA). Tregs were stained with the anti-CD25-PE (M-
A251clone), anti-CD45RA-APC (HI100 clone), anti-CD4-FITC (RPA-T4 clone), and anti-FOXP3-Alexa 
647 (259D/C7 clone) MoAbs, all from Becton Dickinson. Cells were incubated with the conjugated 
MoAbs targeting extracellular antigens for 30 min at room temperature (RT) as indicated by the 
manufacturer’s instruction. The staining of intracellular antigen FOXP3 was performed after the cells’ 
permeabilization with the Human FOXP3 Buffer Set (Beckton Dickinson, Franklin Lakes, NJ, USA). 
After washing, at least 1 × 104 events were evaluated using a FACSCanto flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA) running FACSDiva data acquisition and analysis software 
(Becton Dickinson, Franklin Lakes, NJ, USA). The percentages of CD4 and CD8 T cells were calculated 
with respect to the entire CD3 T cell population, while the percentage of Treg was evaluated with 
respect to CD4 T cells. 
2.4. Intracellular Cytokine Staining 
T cells were stimulated with the anti-CD3 (OKT3 clone, 1 μg/mL) (eBioscence, San Diego, CA, 
USA) and anti-CD28 (CD28.2 clone, 5 μg/mL) (BioLegend, San Diego, CA, USA) MoAbs for 16 h at 
37 °C in the presence of Brefeldin (Sigma-Aldrich, St. Louis, MO, USA) (10 μg/mL). The staining of 
IL-10 positive cells was carried out by fixing the cells with 2% paraformaldehyde (Sigma-Aldrich, 
Saint Louis, MO, USA). Cells were than washed with phosphate-buffered saline (PBS) without Ca2+ 
and Mg2+ + 0.5% saponin (Sigma-Aldrich, Saint Louis, MO, USA) + 10% fetal bovine serum (FBS) 
(Sigma-Aldrich, Saint Louis, MO, USA) and incubated for 30 min with anti-IL-10-PE (JES3-19F1 clone) 
(BioLegend, San Diego, CA, USA) MoAb. Cells were analyzed using a FACSCanto flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA) running FACSDiva data acquisition and analysis 
software (Becton Dickinson, Franklin Lakes, NJ, USA). 
2.5. Statistical Analysis 
Statistical analysis was performed using Graphpad Prism version 6 (Graphpad Software, Inc., 
San Diego, CA, USA). 
Descriptive statistics (average and standard deviation) were used to describe different groups 
of continuous data. Student’s t-test was used to compare groups of continuous variables. Groups of 
categorical data were compared using the Fisher’s exact test. Significance is indicated when p ≤ 0.05. 
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3. Results 
3.1. Patients’ Characteristics and Clinical Response 
Twenty patients met all inclusion criteria and were included in the study. Patients’ 
characteristics are listed in Table 1. As a result of patient matching, no differences in terms of 
clinicopathological variables as well the Eastern Cooperative Oncology Group (ECOG) performance 
status could be identified between the Bev group and the Ctrl group. At the time of blood sampling 
for immunological analysis, 12/20 women (60%) presented intraperitoneal tumor progression, 
whereas the remaining 3/20 (15%) and 5/20 (25%) patients were diagnosed with intraperitoneal plus 
retroperitoneal disease worsening and widespread tumor dissemination, respectively.  
From a clinical point of view, and as confirmed by serial Ca125 serum levels (Table S1), 50% 
(10/20) of patients were judged responders to chemotherapy after six cycles of treatment and were 
equally distributed in each group of interventions (5/10 in the Bev group and 5/10 in the Ctrl group).  
Table 1. Patients’ characteristics. 
 Bevacizumab-Treated Patients Control Group p-Value 
Patient n° 10 10  
Age (median, range) 54 years (42y–67y) 48.5 years (45y–71y) 0.845 
ECOG Performance Status   
 
1 1/10 (10%) 2/10 (20%) 
2 7/10 (70%) 5/10 (50%) 
3 2/10 (20%) 3/10 (30%) 
Tumor Grading at primary diagnosis   
0.628 
I 0 0 
II 4/10 (40%) 2/10 (20%) 
III 6/10 (60%) 8/10 (80%) 
FIGO stage at primary diagnosis   
1 IIIC 8/10 (80%) 7/10 (70%) 








RT at first surgery (cm)   
1 =0 9/10 (90%) 8/10 (80%) 
>0 1/10 (10%) 2/10 (20%) 
Type of recurrence at the time of blood sampling   
0.061 
Intraperitoneal only 7/10 (70%) 5/10 (50%) 
intraperitoneal + retroperitoneal 1/10 (10%) 2/10 (20%) 
widespread 2/10 (20%) 3/10 (30%) 
NACT: Neoadjuvant chemotherapy; PDS: Primary Debulking Surgery; RT: Residual Tumor. 
3.2. Bevacizumab-Treated Patients Showed a Different Immunological Signature Compared with the Control 
Group 
To understand whether bevacizumab treatment impacts the immunological status of ovarian 
cancer patients, the modulation of circulating CD4 and CD8 T cells was firstly analyzed in the Bev 
group and the Ctrl group before (T0) and after III and VI cycles of treatments (Figure 1A). Both CD4 
and CD8 T cells played a critical role in the activation of an effective antitumor immunity. CD8 
lymphocytes exerted their cytotoxic activity by eliminating tumor cells, while CD4 T lymphocytes 
sustained and maintained a CD8 T cell response by cytokine production [9]. A deficiency in the 
activation of one of these two populations induced the development of a failed immunity against the 
tumor. Results obtained from the cancer patients showed that therapies did not modify the 
percentage of CD4 and CD8 lymphocytes in both groups at different time points. CD4 T cells were 
significantly higher in the Bev group at T0 and III compared with the Ctrl goup, although this 
difference disappeared at the end of VI cycles. No difference was observed in CD8 T cells between 
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the two groups, although the ratio CD4/CD8 remained high (>1) up to VI cycles in both groups, 
suggesting a predominance of CD4 T cells during therapies.  
CD8 and CD4 T cells were concurrently analyzed for the expression of CCR7 and CD45RA 
molecules, which identify four different lymphocyte subsets: effector (CCR7−CD45RA+), naïve 
(CCR7+CD45RA+), central memory (CCR7+CD45RA−), and effector memory (CCR7−CD45RA−) T cells. 
Analyzing these T cell subpopulations in the Bev and Ctrl group patients, no significant difference 
throughout the treatment in each patient group and between the two groups were found (data not 
shown).  
Finally, the percentage of Tregs was also examined following the expression of CD4, CD25, and 
FOXP3 markers (Figure 1B). In cancers, Tregs represent one of the most important T cell populations 
as they are able to suppress the activation and/or expansion of antitumor CD4 and CD8 T cells 
through cell–cell contact or by cytokine release [10]. A high percentage of Tregs is associated with a 
poor prognosis in different types of solid tumors [11,12]. In our setting of patients, the results 
demonstrated that the Ctrl group showed a significant decrease in total Tregs from T0 to VI cycles 
(36% vs. 31%, p = 0.03), while no difference was found in the Bev group throughout the therapy. Total 
Tregs were further analyzed according to the combined expression of CD25, FOXP3, and CD45RA 
markers, which identifies three important Treg subpopulations [10]: resting Treg 
(CD25+CD45RA+FOXP3+: rTregs), activated Tregs (CD25highCD45RA-FOXP3-: aTregs), and cytokine-
secreting Tregs with no suppressive activity (CD25+CD45RA-FOXP3+: nsTregs). aTreg have been 
described as terminally differentiated cells that rapidly die after exerting their suppressive activity, 
whereas rTreg proliferate and convert into aTreg both in vitro and in vivo [10]. The analysis revealed 
that bevacizumab-treated patients showed a lower percentage of aTregs and rTregs compared with 
the Ctrl group at T0. This difference persisted until III cycles of treatment in the rTreg subset and 
disappeared after VI cycles, suggesting that these patients exhibited a less suppressive 
immunological profile compared with the Ctrl group at the beginning and in particular after III cycles 
of therapies. 
 
Figure 1. Evaluation of CD4 and CD8 T cell in the bevacizumab (Bev) group and the control (Ctrl) 
group by cytofluorimetry. (A) Analysis of the percentage of CD4 and CD8 T cells derived from 
patients belonging to the Bev group and the Ctrl group before (T0) and after III and VI cycles of 
therapies. CD8 T cells were identified by gating the CD3+CD8+ cells, while the CD4 T cells were 
identified as CD3+CD8−. (B) Histograms represent the percentage of the different regulatory T cell 
subset (total, active, resting, and nonsuppressive) calculated on CD4+CD25+cells. Bev group and Ctrl 
group are represented with black and grey histograms, respectively. 
3.3. Bevacizumab-Treated Patients Showed a Discrete CD4 Effector T Cell Population throughout the 
Treatment 
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Patients belonging to the Bev group and the Ctrl group were then divided in clinically 
responders (R) and clinically nonresponders (N-R) to therapy according to RECIST (Table S1). The 
modulation of CD4 and CD8 T cell was initially evaluated in R and N-R patients of both groups, 
followed by the analysis of the different T cell subsets (Figure 2). The results demonstrated that the 
CD8 T cells derived from bevacizumab-treated patients were not differently modulated in R and N-
R patients, while the CD4 T cells appeared to be significantly higher in the N-R group at the beginning 
and after VI cycles of treatment. Conversely, in the Ctrl group, the CD8 T cells seemed to be 
significantly higher after VI cycles in the R patients compared with the N-R ones, while no significant 
difference was observed in the CD4 T cell population. 
Lymphocytes were also analyzed according to the expression of CCR7 and CD45RA molecules 
(Figure 3). The results demonstrated that in the Bev group and the Ctrl group, the percentage of CD4 
effector T lymphocytes in R patients was higher compared with N-R patients at T0. This difference 
persisted until the end of the therapies for bevacizumab-treated patients, while it had already 
disappeared after III cycles of therapy in the control group. This suggests that Bev treatment, by 
favoring the normalization of the tumor vasculature [13], improves and sustains the circulation of 
effector T cells. 
The other CD4 T cell subsets and the CD8 T cell populations were not significantly modified by 
treatments (data not shown). 
 
Figure 2. Evaluation of CD4 and CD8 T cells in responding (R) and nonresponding (N-R) patients of 
the bevacizumab-treated group and the control group by cytofluorimetry. CD8 T cells were identified 
by gating the CD3+CD8+ cells, while the CD4 T cells were identified as CD3+CD8−. 
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Figure 3. Analysis of CD4 and CD8 T cell subsets were carried out using the anti-CD3, anti-CD8, anti-
CCR7, and anti-CD45RA MoAbs. CD8 T cells were identified by gating the CD3+CD8+ cells, while the 
CD4 T cells were identified as CD3+CD8−. Dot plots show the expression of CD45RA and CCR7 
molecules that identify different T cell subsets (T effector: CD45RA+CCR7−; T central memory: 
CD45RA−CCR7+, T naive: CD45RA+CCR7+, and T effector memory: CD45RA−CCR7−) at T0 and after 
III and VI cycles of therapy. Histograms represent the median values of the percentage of effector T 
cells (CD45RA+CCR7−) of 10 patients (five patients of R and N-R of both Bev group and Ctrl group) ± 
standard deviation. Black and grey columns correspond to responding and nonresponding patients, 
respectively. 
3.4. Tregs Were Modulated in Bevacizumab-Treated Patients during Therapies 
To assess whether the treatment schedule and/or the clinical response could be associated with 
the modulation of the Treg subsets, the percentage of circulating Tregs after III or VI treatment cycles 
were compared with the baseline value at T0, and the analysis was expressed as fold increase 
(%TregIII/%TregT0 or %TregVI/%TregT0) (Figure 4). After III cycles of treatment, the level of the 
entire Treg population was significantly higher in R patients compared with N-R patients in the Bev 
group. This increase was ascribed to the nsTreg subset being significantly higher in R compared with 
N-R patients. These differences between R and N-R patients disappeared after VI cycles of 
bevacizumab treatment. In contrast, the control group did not show any difference in the percentage 
of Tregs between R and N-R patients during therapies, and no difference between the Bev and Ctrl 
patients was observed.  
 
Figure 4. Total and non-suppressive Treg (totTreg and nsTreg, respectively) evaluated as fold increase 
after III or VI cycles of therapy compared with T0 (%TregIII or %TregVI/%TregT0). Black and grey 
columns correspond to Bev group and Ctrl group, respectively. 
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3.4. Bevacizumab-Treated N-R Patients Had Higher Level of IL10+ T Cells Compared to R Patients 
Because IL10, such as TGFβ, is one of the most important cytokines released by Tregs [14] that 
is able to downregulate Th1 cytokine production and block NF-κB activity [15], T cell derived from 
patients in the Bev group were analyzed for their capacity to produce IL10 as intracellular staining 
(Figure 5). These patients exhibited a significant increase in IL10+ cells from T0 up to VI cycles of 
therapy. Analyzing the data as fold increase of the percentage of IL10+ cells after III and VI cycles of 
therapy compared with T0 (%IL10III/%IL10T0 or %IL10VI/%IL10T0) between R and N-R patients, 
significant high levels of IL10 were found in N-R patients after III cycles, suggesting an enhancement 
of the immunosuppression during the bevacizumab treatment in this group. This increase 
disappeared after VI cycles (p = 0.08) of therapy.  
  
Figure 5. Evaluation of IL10+cells at T0 and after III and VI cycles of treatment in bevacizumab patients 
and fold increase of the percentage of IL10+cells after III and VI cycles of therapy compared with T0 
(%IL10 III or %IL10 VI/%IL10 T0) in R and N-R patients belonging to the Bev group. 
4. Discussion 
Multi-treated progressive ovarian cancer still remains the most challenging disease setting for 
gynecologic oncologists, and so far, no global consensus has been met about how/how long patients 
should be continued to be treated [16]. Indeed, all these patients progressively develop 
pharmacoresistance for the majority of conventional chemotherapy drugs, and the only option left (if they 
are not eligible for phase I clinical trials) is to retreat them with previously adopted compounds [17]. 
Among biological agents that have obtained FDA/EMA approval in compassionate ovarian cancer 
setting, bevacizumab has been the first to enter into clinical practice after showing its ability to 
improve patients’ quality of life and also reduce paracentesis frequency for women suffering 
malignant ascites [5].  
The effects of bevacizumab on patients’ immune system are still not completely elucidated, 
although a strong rationale about the interplay between its ligand (VEGF) and the host’s immune 
response suppression has already been shown [18]. In particular, three different mechanisms related 
to VEGF-mediated immunosuppression have been assessed so far: inhibition of dendritic cell 
maturation [19–21], reduction of T cell tumor infiltration [22], and promotion of inhibitory cells in the 
tumor microenvironment [23]. 
In this scenario, the present study adds new evidence to the body of knowledge concerning the 
immune effects of bevacizumab in advanced cancer patients by showing that (1) ovarian cancer 
patients not treated with bevacizumab-based chemotherapy seem to have a more 
immunosuppressive profile with the presence of a rTreg population that persists until the end of III 
cycles of therapy; (2) patients that clinically respond to bevacizumab treatment show a discrete 
population of effector T cells at the beginning of therapy that is maintained throughout the treatment; 
(3) Tregs are mainly represented by non-suppressive regulatory T cells in clinically responding 
bevacizumab patients compared with nonresponding patients and are also stably maintained in this 
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ratio (nsT reg > sup T reg) throughout the treatment; (4) after three cycles of treatment, 
nonresponding bevacizumab patients produce more immunosuppressive IL-10 cytokine compared 
with responding patients.  
It should be pointed out that these results were obtained by comparing two groups of patients 
that were matched for all clinical characteristics. Particularly important is to notice that the 
performance status was similar among the two groups; this variable has been significantly associated 
with the immunological effects and response to several therapies [24]  
Other authors have observed an impact of bevacizumab-based regimens on the 
immunosuppressive status of cancer patients in different cancer settings. In particular, it was recently 
reported that, for glioblastoma patients subjected to radiation plus temozolomide (TMZ) and 
bevacizumab, the absolute number of peripheral Tregs significantly decreased following treatment [25]. 
Furthermore, the addition of bevacizumab to standard radiation and TMZ appeared to decrease the 
number of circulating Tregs compared with radiation plus TMZ alone. On the contrary, they also 
noticed a significant decrease in the absolute number of cytotoxic CD8 (CD107a+), effector memory 
CD8, and naïve CD4 T cells in the group of bevacizumab-treated patients.  
Our results follow and confirm the original observation by our group [6] in which a significant 
reduction of Tregs and an increase in the proportion and function of effector CD8 T cells were found 
in an end-of-life ovarian cancer patient treated with low-dose intraperitoneal bevacizumab for 
malignant ascites.  
We also showed that responding bevacizumab-treated patients reported a higher percentage of 
circulating CD4 effector T cells compared with nonresponding bevacizumab patients, confirming 
what has already been observed in metastatic colorectal cancer [2]. This data has key implications in 
the current panorama of oncological clinical approach. Indeed, it is reasonable to suggest that the 
circulating effector T cells recruited and sustained by bevacizumab treatment, thanks to its ability to 
restore tumor microvascular normalization [13], could be expanded by the administration of 
checkpoint inhibitor agents, thus giving a strong biological rationale for the combination of 
immunotherapy with bevacizumab antiangiogenetic therapy. In support of this consideration, tumor 
tissue derived from metastatic renal cell carcinoma (mRCC) patients treated with anti-PD-L1 
atezolizumab plus bevacizumab was recently found to show an increase in intratumoral CD8 T cells 
as well as an increase in intratumoral MHC-I, Th1 and T-effector markers, and chemokines. Trafficking 
lymphocytes also increased in tumors following bevacizumab and combination treatment [26]. 
We finally observed that bevacizumab responding patients showed significant lower circulating 
immunosuppressive IL-10 cytokine levels compared with non-responding patients, thus confirming 
the effect of bevacizumab in reducing patients’ immune suppression. A similar finding was recently 
obtained in breast cancer neoadjuvant setting [27]. Patients treated with bevacizumab-included 
neoadjuvant chemotherapy showed a global decrease in circulating cytokines levels, such as VEGF-A, 
IL-12, IP-10, and IL-10. In addition, the decrease in IL-10 serum levels was confirmed to be even 
greater in response to bevacizumab treatment in metastatic colorectal cancer setting [28].  
To our knowledge, this is the first study analyzing the immunological effects of bevacizumab-
based treatment in women with advanced ovarian cancer in relation to their clinical response.  
However, several significant limitations are present in this study. The first is the restricted 
number of patients that were retrospectively and not randomized selected. Moreover, there were no 
data regarding the immune fitness of the patients at diagnosis before the beginning of all therapies. 
Finally, although no differences in clinicopathological variables were identified, the two groups 
analyzed showed several differences in their immunological signature at T0. These differences could 
be ascribed to the several chemotherapy treatments (e.g., taxol, bemcitabine, pegilated liposomal, 
doxorubicin etc.) that differently impact the immunological system [29], together with the capacity 
of the immunological signature of each patient to differently respond to the same environmental 
factor, such as chemotherapy and surgery. In this setting, a discrete population of effector CD4 T cell 
is present in any case in both populations of patients independently from previous treatment. This 
cell subset is the one that appears to be affected by the bevacizumab regimen, and this could impact 
clinical outcome. 
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Another important point is the occurrence of leukopenia in multi-treated patients, which 
represents an important prognostic factor in patients with advance malignances [30]. In our setting, 
patients were affected by mild/moderate leukopenia that was non-clinically significant.  
The strengths of this study can be summarized as follows: (1) the population involved was 
homogeneous for histology and clinical stage; (2) the patients belonging to the two groups 
(bevacizumab-treated and control) were matched for age, tumor grading, FIGO stage, type of 
primary treatment strategy (primary debulking surgery versus neoadjuvant chemotherapy followed 
by interval debulking surgery), tumor residual at first surgery, and type of recurrence at the time of 
blood sampling, thus minimizing selection bias; (3) blood sampling was carried out for all patients at 
the same times of treatment, i.e., at T0 and after three and six cycles of therapy. 
5. Conclusions 
In conclusion, this study sheds a light on the strong need to routinely include 
immunomonitoring in oncological clinical protocols of patients at follow-up during the course of 
antiangiogenetic therapy administrations, with the final aim being to identify early the subset of 
patients who can mostly benefit from its adoption. Furthermore, the study provides a first rationale 
regarding the positive immunologic impact of combining bevacizumab with checkpoint inhibitors. 
Confirmatory studies carried out on larger cancer patient populations are warranted.  
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Ca125 levels 
of patients belonging to Bev group and Ctrl group. 
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Abstract
Tyrosine kinase inhibitors (TKIs) target angiogenesis by affect-
ing, for example, the VEGF receptors in tumors and have
improved outcomes for patients with metastatic renal cell car-
cinoma (mRCC). Immune checkpoint inhibitors (ICIs) have
also been proposed for treatment of mRCC with encouraging
results. A better understanding of the activity of immune cells in
mRCC, the immunomodulatory effects of TKIs, and the char-
acteristics defining patients most likely to benefit from various
therapies will help optimize immunotherapeutic approaches. In
this study, we investigated the influence of the TKI pazopanib on
dendritic cell (DC) performance and immune priming. Pazo-
panib improved DC differentiation and performance by pro-
moting upregulation of the maturation markers HLA-DR, CD40,
and CCR7; decreasing IL10 production and endocytosis; and
increasing T-cell proliferation. PD-L1 expression was also down-
regulated. Our results demonstrate that pazopanib inhibits the
Erk/b-catenin pathway, suggesting this pathway might be
involved in increased DC activation. Similar results were con-
firmed in DCs differentiated from mRCC patients during pazo-
panib treatment. In treated patients pazopanib appeared to
enhance a circulating CD4þ T-cell population that expresses
CD137 (4-1BB). These results suggest that a potentially
exploitable immunomodulatory effect induced by pazopanib
could improve responses of patients with mRCC in customized
protocols combining TKIs with ICI immunotherapy. Cancer
Immunol Res; 6(6); 711–22. 2018 AACR.
Introduction
Tumor progression requires angiogenesis. Proangiogenic
factors, such as VEGF, that are induced by hypoxia or oncopro-
teins can alter the equilibrium between pro- and antiangiogenic
factors, resulting in the generation of new blood vessels, mostly
with altered endothelium structure. Proangiogenic factors are
involved in the generation of immunosuppression in tumors.
Tumor neoangiogenesis is associated with immature and tolero-
genic dendritic cells (DCs) and increased number of myeloid-
derived suppressor cells (MDSCs), the activation of regulatory
T cells (Tregs), and recruitment of tumor-associatedmacrophages
(TAMs) in the tumor bed (1).
Various antiangiogenic andmultitargeted compounds, includ-
ing bevacizumab, sunitinib, pazopanib, sorafenib, axitinib, len-
vatinib, and cabozantinib, have entered the clinic for use against
tumors that depend on angiogenesis (2–4). For metastatic
renal cell carcinoma (mRCC), VEGFR-directed tyrosine kinase
inhibitors (TKIs) have demonstrated clinical benefits including
improvements in progression-free survival and overall survival
(5). These compounds, which target VEGF and its receptors, are
likely to affect the immune repertoire of cells and molecules
that interact with the growing tumor. Immunosuppression
appears to be downregulated in mRCC patients treated with
sunitinib or axitinib, whose Treg and MDSC cell populations are
affected. Sorafenib has the opposite effect by reducing antigen-
specific T-cell induction in vitro (6–11). The different selectivities
and affinities of the various drugs are thought to account for the
diverse effects on myelopoiesis and immune cells (12).
As immunotherapy using immune checkpoint inhibitors is
moving to clinical application for mRCC, we must understand
the immune consequences of TKI therapy. In the CheckMate
025 randomized phase III trial, Escudier and colleagues observed
inmRCCpatients improved overall survival and favorable hazard
ratio for the anti–PD-1 nivolumab group that had previously
received first-line treatment with pazopanib (HR, 0.60; 95% CI,
0.42–0.84); such results suggest an immune effect on the tumor
microenvironment (13).
TKIs seem to be more effective in mRCC, suggesting that
the requirement for angiogenesis increases as the disease pro-
gresses. In order to achieve maximum response from anti–PD-1
immunotherapy, the patient must be prepared to receive an
immunotherapeutic regime that will expand activated and spe-
cific T cells. We have addressed this issue by studying DC perfor-
mance at concentration of sunitinib and pazopanib found in
plasma. DCs are antigen-presenting cells that prime antigen-naive
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T cells and perform cross-priming, thus presenting antigens both
in HLA class I and II to activate immune responses. Optimal DCs
express costimulatory molecules such as CD40, CD83, CD86,
HLA-DR, and to a lesser extent CD14 and PD-L1. In order to
migrate to the lymph node for cross talk with effector cells, DCs
must express the CCR7 marker. These parameters relate to T-cell
priming and activation. Failure to sustain these hallmarks will
lead to tolerogenic DCs that will dampen antitumor immunity
(14, 15).
We report here results that identify the TKI pazopanib as an
immune stimulator, which exerts its effects by influencing DC
differentiation and maturation. This activation is mediated by
targeting and downregulating p-Erk and b-catenin pathway.
The impact of this immune activation mediated by DCs was
investigated in mRCC patients undergoing TKI treatment. Our




Human monocyte-derived DCs were generated from periph-
eral bloodmononuclear cells (PBMCs) of healthy donors (Ethical
Committee Protocol, RIF.CE: 4212) and of mRCC patients
(Ethical Committee Protocol, RIF.CE: 4181). Monocytes
(CD14þ) were purified from PBMCs after Ficoll–Hypaque gradi-
ent (1,077 g/mL; Pharmacia LKB) by Human CD14-Positive
Selection Kit (StemCell Technologies) and cultured (5  105
cells/mL) in RPMI 1640 (Hyclone) supplemented with
2 mmol/L L-glutamine, penicillin 100 U/mL, streptomycin
100 mg/mL (Sigma-Aldrich), with 5% heat-inactivated Fetal Calf
Serum (FCS; Hyclone). Fifty ng/mL rhGM-CSF (R&D Systems)
and 2,000 U/mL rhIL4 (R&D Systems) were added at day 0 and 2.
Immature DCs (iDCs) were collected at day 5 and matured with
cytokine cocktail (rhIL1b, IL6, TNFa and PGE2; all purchased by
R&D Systems) for 16 hours. Sunitinib (50 ng/mL; Sigma-Aldrich)
and pazopanib (19 mg/mL; Sigma-Aldrich) were dissolved in
dimethyl sulfoxide (DMSO; Euroclone) and added to the culture
during DC differentiation.
Immune phenotype
DC phenotype was analyzed by flow cytometry using the
following monoclonal antibodies (mAb): anti–HLAII-DR-FITC,
anti–CD86-FITC, from BD Biosciences, anti–CD14-PE,
anti–CCR7-FITC, anti–CD83-PE, anti–CD40-PE, anti–PD-L1-PE
from BioLegend and anti–VEGR-1 from R&D Systems. MoAbs
anti–IgG1-FITC and anti–IgG1-PE (BioLegend) were used as
isotype controls.
For immune profile evaluation, PBMCs were isolated from
blood samples (50 mL) from six mRCC patients by Ficoll–
Hypaque at different times (Ethical Committee Protocol, RIF.CE:
4181): before treatment with sunitinib or pazopanib (T0), during
treatment (T1: 1month of treatment, T2: 2months, T3: 3 months









All mAbs were purchased by BD Biosciences and BioLegend.
Flow cytometric analysis was performed using FACSCanto flow
cytometer running FACS Diva data acquisition and analysis
software (BD Biosciences). Catalog numbers and clones for every
antibody used are listed in Supplementary Table S1.
Microvesicle isolation
Microvesicles were isolated from supernatants of DCs dif-
ferentiated with and without suninitib and pazopanib. Super-
natants were centrifuged at 13,000  g for 30 minutes at 4C.
Microvesicles were then stained with anti–PD-L1 (BioLegend)
and acquired by FACSCanto flow cytometer and analyzed by
FACS Diva software. Anti–IgG1-PE (BD Biosciences) was used
as isotype control. Fluorescent Nile Red Particles (0.1–0.3 mm,
Spherotech Inc.) were used as size control.
Western blot analysis
ImmatureDCs andmatureDCs (iDCs andmDCs, respectively)
with and without sunitinib and pazopanib were lysed using the
NP-40 solution (Biocompare) in the presence of phenylmethyl-
sulfonyl fluoride (1 mmol/L, PMES) and protease inhibitors
(1X; Sigma). Proteins obtainedwere quantified by Bradford assay,
were resolved using 4% to 12% SDS-PAGE gel and transferred to
nitrocellulose. After blocking, membranes were incubated with
rabbit anti–b-catenin (Bethyl Laboratories Inc.; 1:1,000), rabbit
anti-pErk42/44 (Erk1/2; Cell Signaling Technologies; 1:1,000),
mouse anti–b-actin (Cell Signaling Technologies; 1:1,000) and
mouse anti–NF-kB (p105/p50; Cell Signaling Technologies;
1:1,000), followed by peroxidase-conjugated goat anti-rabbit or
anti-mouse IgG (HþL; Jackson Immuno Research Laboratories;
1:20,000). Protein bands were detected with ImmobilonWestern
(Millipore Corporation) following the manufacturer's instruc-
tions. The density of protein bands was analyzed by Image J
software and was normalized in terms of average intensity of
bands of each protein per average intensity of bands of b-actin.
Endocytosis assay
FITC-dextran (1 mg/mL; Molecular Probes) was added to
untreated iDCs and mDCs and differentiated with sunitinib and
pazopanib for 2 hours at 37C. After washing, cells were acquired
by FACSCantoII flow cytometer and analyzed by FACSDiva
software. DCs incubated with FITC-dextran for 2 hours at 4C
were used as negative controls.
Cytokine production
Culture supernatants from iDCs and mDCs untreated or dif-
ferentiated with sunitinib and pazopanib and sera from mRCC
patients were collected and analyzed using the ProcartaPlex
Human Inflammation Panel (20 Plex; eBioscence). Samples
were measured by BioPlex Magpix Multiplex Reader (Bio-Rad)
and data analysis was performed using Bioplex Manager MP
software (Bio-Rad).
T-cell proliferation
T lymphocytes were purified from Ficoll–Hypaque gradient
(1,077 g/mL; Pharmacia LKB) followed by CD3 immunomag-
netic isolation (StemCell). T cells were then cocultured in a
96-well round-bottom microplate (Costar) with allogeneic iDC
and mDCs differentiated with and without sunitinib and pazo-
panib (DCs: T cells, 1:5) in the presence of PHA (5 mg/mL) for
4 days at 37C. T cells were pretreated with CarboxyFluorescein
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Succinimidyl Ester (1 mmol/L, CFSE; Life Technologies) and cell
proliferation was monitored through progressive halving of fluo-
rescence using FACSCantoII flow cytometer and analyzed by
FACSDiva software (BD Biosciences). Results were reported as
the percentage of proliferation increase of T cells cultured with
DCs treated with sunitinib and pazopanib compared with T cells
cultured with DCs alone.
T cells were also cultured in 6-well round-bottom micro-
plates (Costar) in the presence of sunitinib (50 ng/mL) and
pazopanib (19 mg/mL) up to 24 hours. Proliferation was
evaluated by FACSCantoII flow cytometer and analyzed by
FACSDiva software.
Statistical analysis
Descriptive statistics (average and standard deviation) were
used to describe the various data. ANOVA test was used to analyze
statistical differences between three groups. Student paired t test
was used to compare two groups. Significance is indicated when
the P value was less than 0.05.
Results
Pazopanib improves DC activation and increases expression
of DC-maturation markers
To investigate the capacity of TKIs to influence DC differ-
entiation and maturation in vitro, the expression of CD14,
HLA-DR, CD86, CD83, CCR7 and CD40 was evaluated by flow
cytometry on monocyte-derived DCs of healthy donors.
Untreated DCs were used as control. The exposure to concen-
trations of sunitinib and pazopanib found in plasma affected
the phenotype of immature and mature DCs differently
(Fig. 1A and B). Sunitinib did not affect DC differentiation
and maturation, but DCs cultured in the presence of pazopa-
nib were more activated. Pazopanib modified iDC phenotype,
significantly increasing the expression of HLA-DR and CD40
molecules, compared with that of iDCs alone (HLA-DR
P < 0.01) and iDC treated with sunitinib (HLA-DR P < 0.05;
CD40 P < 0.05; Fig. 1A). The average values of mean fluores-
cence intensity (MFI) indicated upregulation of CD83 in DCs
differentiated with pazopanib. On the other hand, CD14
expression was downregulated by pazopanib during differen-
tiation. Similar results were obtained after DC maturation
(Fig. 1B). mDCs cultured in presence of pazopanib significant-
ly upregulated the expression of CCR7 and CD40 molecules
compared with untreated mDCs (CCR7 P < 0.05; CD40 P <
0.05) and sunitinib-treated mDCs (CCR7 P < 0.05), suggesting
that pazopanib enhances activation status of both immature
and mature DCs.
VEGF-R1 expression, which is the target of both TKIs, was
unaltered by treatment of DCs with pazopanib or sunitinib
(Supplementary Fig. S1A)
PD-L1 is downregulated in pazopanib-generated DCs
The capacity of DCs to stimulate T cells depends on the
balance between costimulatory and coinhibitory signals.
Increased expression of costimulatory marker such as CD40
or CD83 can facilitate T-cell activation, whereas increased
expression of inhibitory markers such as PD-L1 contributes to
T cell-negative regulation (16). To evaluate the expression of
coinhibitory signals in DCs in response to TKI treatment, we
analyzed the expression of the PD-L1 both on DCs and on shed
microvesicles (Fig. 2). During iDC differentiation, only pazo-
panib began to decrease PD-L1 expression, compared with un-
treated DC and DCs differentiated with sunitinib (Fig. 2A). The
decrease in expression became significant (P < 0.01) in DCs
after maturation (Fig. 2B).
Microvesicles released by the DCs also showed a decrease in
PD-L1 expression: PD-L1 expression on microvesicles released
by DCs treated with pazopanib was lower than that on micro-
vesicles obtained by untreated DCs and DCs treated with suni-
tinib (Fig. 2C). The difference in expression of PD-L1 between
microvesicles of mDCs and mDCs treated with pazopanib was
statistically significant (P < 0.05).
Pazopanib treatment reduces immunosuppression
downregulating IL10 production by DCs
The production of cytokines such as IL10 and IL12 during DC
maturation can influence the capacity of DCs to alter Th1 or Th2
immune responses (17). Several chemokines released by DCs,
such as CXCL-10, promote tumor-reactive effector T-cell recruit-
ment (18). Thus,we evaluated cytokines and chemokines released
by untreated DCs and DCs treated with TKIs (Fig. 3A). We
observed a significant reduction (P < 0.05) of IL10 in iDCs and
mDCs treated with pazopanib compared with untreated DCs
(both iDC and mDCs) and DCs treated with sunitinib (both iDC
and mDCs). The balance between IL12/IL10 and CXCL-10/IL10
favored immune activation when DCs were generated with pazo-
panib (Supplementary Fig. S1B).
Pazopanib-treated DCs are able to increase T-cell activity
DCs must possess specialized features to act as good antigen-
presenting cells. In addition to expression of costimulatory
molecules and release of cytokines, other indicators of DC
function and quality include their capacity for endocytosis and
T-cell activation. The exposure to maturation stimuli induces
changes including downregulation of endocytosis and increase
of antigen presentation to T cells. We evaluated the endocytic
capacity of DCs treated with TKIs and untreated DCs by
fluorescein isothiocyanate (FITC)-dextran uptake and followed
by flow cytometry (Fig. 3B). We determined the ratio of the
fluorescence from positive (dextran uptake obtained after
2 hours at 37C) and negative (dextran uptake after 2 hours
at 4C) samples. The results show that pazopanib reduced
endocytosis capacity by 29% for iDCs treated with pazopanib
compared with untreated DCs (1.42 ratio vs. 2, respectively),
and by 40% compared with iDCs treated with sunitinib (1.42
vs. 2.33). The trend persisted after maturation: the endocytic
capacity of pazopanib-treated mDCs was 42% lower than that
of mDCs (0.8 ratio vs. 1.37) and 57% lower than that of
sunitinib-treated mDCs (0.8 vs. 1.82).
We then analyzed the capacity of DCs to stimulate the pro-
liferation of allogeneic T cells (Fig. 3C). Lymphocytes, pretreat-
ed with CFSE, were cocultured with DCs and proliferation was
evaluated after 4 days through progressive halving of fluores-
cence by flow cytometry. The results, plotted as percentage of
fold increase (% of proliferation obtained as ratio between
T cells stimulated by pazopanib-DCs/DCs or sunitinib-DCs/
DCs), showed that when DCs were differentiated in the pre-
sence of pazopanib, they acquired a greater capacity to stim-
ulate T cells than either untreated DCs (20% fold increase for
iDCs, 5% for mDCs) or sunitinib-treated DCs (14% for iDC,
5,1% for mDCs). No effect was observed on T cells cultured
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Pazopanib modulates DC phenotype. The MFI values of DC phenotypic markers from healthy donors are shown. The cells were differentiated from
monocytes in presence of pazopanib (20 mg/mL) and at day 5 iDCs were collected and matured with cytokine cocktail (rhIL1b, IL6, TNFa, and PGE2).
Untreated DCs and DCs differentiated with sunitinib (50 ng/mL) were used as controls. The concentration of pazopanib and sunitinib used for
the culture corresponds to serum levels achieved in TKI-treated patients. A, The phenotype of iDCs; B, The phenotype of mDCs. The bars correspond
to the average MFI values among donors. Statistical significance was determined by ANOVA test when comparing three groups and by Student
paired t test for two groups.  , P < 0.05;  , P < 0.01, Student t test.
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alone for 24 hours in the presence of either TKI (Supplementary
Fig. S2).
Pazopanib affects DC differentiation by inhibiting p-Erk/
b-catenin signaling
The Wnt-b-catenin pathway, particularly in DCs, regulates
the balance between tolerance and immune response (19).
Loss of b-catenin impairs the ability of DCs to induce Tregs
(20), instead the activation of b-catenin pathway increases the
capacity of DC to release IL10 and promote immune tolerance,
(21, 22). In DCs, b-catenin signaling synergizes with other
pathways, such as the Erk pathway, to induce anti-inflammatory
cytokines and proliferation of Tregs. Erk1/2 signaling retards the
phenotypic and functional maturation of monocyte-derived
human DCs (23).
To evaluate whether changes in DC functional activity were
due to signaling differences, we examined DC intracellular
pathways. Untreated DCs or DCs differentiated in the pre-
sence of sunitinib or pazopanib were lysed and probed with
anti–p-Erk 1/2, anti–b-catenin and anti–NF-kB by western blot
(Fig. 4). DCs treated with pazopanib expressed less p-Erk 1/2
than did DCs treated with sunitinib or untreated DCs. This
downregulation associated with a significant reduction of
b-catenin expression (iDCs and sunitinib-iDCs vs. pazopa-
nib-iDCs P < 0.05; mDCs vs. pazopanib-mDCs P < 0.05). In
both pazopanib-iDCs and pazopanib-mDCs, p-Erk1,2 and
b-catenin antibodies detected a weaker signal than in untreated
DCs and DCs treated with sunitinib, suggesting that pazopanib
could act through these pathways. We analyzed the activation
of NF-kB, which is essential for DC development and survival
and regulates DC maturation. Results indicated that NF-kB acti-
vation was similar in all iDCs tested. Although the p50 signal was
weaker in mDCs treated with pazopanib, the balance between
all intracellular pathways favored the activation pathway.
Modulation of DCs generated frommRCCpatients treatedwith
pazopanib or sunitinib
To confirm the pazopanib immune-priming effect in pati-
ents, we analyzed monocyte-derived DCs differentiated from
mRCC patients during TKI treatment. DCs were differentiated
in vitro by standard methodology without the addition of
TKIs. Fig. 5 shows the phenotype of DCs generated from PBMCs
of RCC patients after one month of pazopanib or sunitinib
treatment. CD14, a marker of DC immaturity, was less expres-
sed in iDCs from patients treated with pazopanib (P < 0.01)
than patients treated with sunitinib confirming data obtained
in vitro. Moreover, DCs (both iDCs and mDCs) from pazopanib-
treated patients expressed more of the activation markers HLA-
DR and CCR7 and less PD-L1 (mDCs; P < 0.01) as compared
with DCs generated from sunitinib-treated patients.
For one patient, we evaluated the modulation of some DC
markers differentiated before (T0) and during pazopanib ther-
apy (T1: after 1 month of treatment, T2: after 2 months) and
results are shown in Supplementary Fig. S3A. As with DCs
generated in vitro with pazopanib, iDCs from this mRCC







































































































Pazopanib treatment reduces PD-L1
expression. PD-L1 expression by
untreated DCs and treated with
sunitinib and pazopanib (iDC in A and
mDC inB). Data are reported as values
of MFI and the bars correspond to
average of these values. C,
Microvesicles released by DCs and
analyzed by flow cytometry are
represented on forward scatter/side
scatter dot plot. The histogram shows
the expression of PD-L1 in terms of MFI
on microvesicles obtained by
untreated DCs (black columns), by
DCs differentiated with sunitinib (light
gray column) and by DCs
differentiated with pazopanib (dark
gray column). ANOVA test was used
to compare three groups. Student
paired t test for twogroups.  ,P<0.05;
 , P < 0.01; Student t test.
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expression of HLA-DR at T2 and CD40 at T1 and T2. Expression
of the coinhibitory molecule PD-L1 decreased during pazopa-
nib treatment, both in iDCs and mDCs, confirming that pazo-
panib boosts DC activity.
Immune profile of mRCC patients during TKI treatment
The priming of DCs by pazopanib could impact the immune
repertoire in the peripheral blood ofmRCCpatients. To verify this
hypothesis, we followed and monitored longitudinally mRCC
patients undergoing TKI therapy, either pazopanib or sunitinib.
Patients had different previous therapies although all of the
patients belonged to the same risk group. Six patients in treatment
with TKIs for mRCC underwent peripheral blood sampling at
different time points and PBMCs were isolated and analyzed by
flow cytometer in order to investigate the evolution of patients'
immunological profile during TKI administration. The clinical
profile and the schedule of blood sampling is showed in Fig. 6A.
Patients 1, 2, and 3 received pazopanib, whereas patients 4, 5, and
6 received sunitinib. The immunoassays were performed when
possible at different time points, as shown in the figure. Two
patients (patient 3 and 5) showed progressive disease and one of
these died from the disease. The other four are still in treatment
with TKIs.
Several immunological parameters were evaluated for each
patient at each time point considering the limited amount
of blood sampling (Fig. 6). In particular, we analyzed T-cell
subpopulations, their activation status (CD137 expression),
their proliferation ability as assessed by expression of Ki67,
the immunosuppression as a percentage of Tregs, and T-cell
exhaustion as assessed by expression of checkpoint inhibitors
such as PD-1, CTLA-4, and Tim-3. Pro- and anti-inflammatory
cytokines were evaluated in serum of patients. Only the
assays for which we had sufficient patient samples are shown
in Fig. 6.
We observed that pazopanib seemed to induce an increased
number of CD3þCD137þ T cells (Fig. 6B). In patient 1, for
example, activated (CD137þ) CD4þ T cells were 30% of the
activated CD3þ T cells at time T2, compared with T0 (before
pazopanib therapy, 0.3%of activated CD3þ T cells) and T1 (4.7%
of CD3þ T cells). At T5, we observed a decrease of CD4þ and
CD8þ CD137þ T-cell populations. In the same patient, plasma
levels of IL6 dropped from T0 to T2, both IL4 and CXCL-10
increased at T1 and T2, and ICAM decreased at T2. Ki67 expres-
sion, a proliferation signal for T cells, was higher at T2 than at
other time points. Patient 2 had fewer CD137þ T cells from time
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Figure 3.
DCs activated by pazopanib modulate cytokine and chemokine release, reduce endocytic capacity and increase T-cell proliferation. A, The amount of
IL10, IL12, and CXCL-10 was evaluated in differently generated DC supernatant by Luminex multiplex beads analysis. The results correspond to the
mean obtained from 10 independent experiments  SD. B, The endocytic capacity of iDCs and mDCs differently generated was evaluated as FITC-dextran
uptake (1 mg/mL/106 cells). Open histograms represent the dextran uptake obtained after 2 hours at 37C (positive), whereas filled histograms show
the dextran endocytosis after 2 hours at 4C (negative control). Results are representative of one donor out of four. The values reported on histogram
indicate the ratio between MFI of positive and negative control of four independent experiments for each DC condition. C, The capacity of DCs to
prime allogenic T-cell response in vitro was tested evaluating T-cell proliferation ability through progressive halving of CFSE fluorescence using
FACSCanto flow cytometry. Results are reported as a percentage of increase of T-cell proliferation capacity of three independent experiments of DCs
treated with pazopanib compared with sunitinib-differentiated DCs and untreated DCs. ANOVA test was used to compare three groups. Student paired
t test for two groups.  , P < 0.05.
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Ki67þ T cells increased. Patient 3, who was monitored during
pazopanib treatment and immediately after progression, show-
ed enhancement of CD4þCD137þ T cells at T3 (54%) compared
with T0 (24.9%) and T1 (23.2%). This population decreased
during progression under nivolumab treatment (T4, T5). This
patient's Treg population was unchanged. PD1þ T cells increased
slightly from T0 to T1, then decreased during pazopanib and
nivolumab treatment.
When we analyzed mRCC patients treated with sunitinib, we
observed that CD137þ T cells were less evident, thus suggesting
that this population could be influenced by the effect of
pazopanib. In Patient 4, under sunitinib therapy,
CD4þCD137þ T cells were barely detectable at all three time
points. This patient presented with 29% of T cells being
CD8þCD137þ T cells at T1; however, this population decreased
to 14% at T2 and T3. In the same patient, the serum concen-
trations of IL10 were increased at T2 compared with T1,
whereas serum concentrations of IL12, IL4, and CXCL-10
decreased. In accordance with the increase of IL10, we observed
an increase of Treg cells during sunitinib treatment, accompa-
nied by upregulation of CTLA-4 expression on T cells at T3.
Patient 5 showed a similar decreasing trend in CD137þ T-cell
population. Coinhibitory markers, such as CTLA-4 and Tim-3,
increased during sunitinib treatment. Ki67þ T cells were
decreased, and Treg cells were reduced. Patient 6 presented
low and stable fractions of CD137þ T cells during sunitinib
treatment when there time points were analyzed, although
CD3þCD137þ T cells doubled at T7. At the same time IL10
and IL4 decreased compared with T5, and IL12 slightly
increased. Tregs decreased at T7 but increased at T9.
Discussion
RCC is the tumor that has most benefited from clinical use of
TKIs. The clear cell histotype drives VEGF overproduction via
inactivation of the tumor-suppressor Hippel–Lindau (VHL) gene



















































































































































































































Pazopanib modulates DC signaling
turning off the p-Erk/b-catenin
pathway. Western blotting of iDCs
(left) and mDCs (right) untreated and
generated in presence of sunitinib and
pazopanib. Samples were analyzed
for p-Erk 1/2 (42–44 kDa), b-catenin
and for the presence of NF-kB.
b-Actin was used as a loading control.
Proteins were resolved in 4% to 12%
SDS-PAGE gel. Densitometric
evaluation of the signals for b-catenin,
p-Erk1/2 and p50 were normalized to
the levels of b-actin (under the blot).
ANOVA test was used to compare
three groups. Student paired t test for
two groups.  , P < 0.05.
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(24, 25). Immune-targeting molecules have added additional
possible treatment choices for RCC. The increase in treatment
options has added complexity to clinical questions on how to
choose first-line treatment and treatments after recurrence (26).
Although VEGF- and mTOR-targeted therapies have improved
clinical outcome in metastatic RCC, durable responses remain
rare despite efforts to design sequential or combined treatment
modalities.
RCC is been considered an immunogenic tumor and therapy
with cytokines such as IL2 and IFNa has been used although the
responses have beenmild and associated with toxicity. Long-term
responses and complete remissions have been occasionally
observed in mRCC patients treated with immunotherapy
(27, 28). The induction of an immune response such as the one
elicited by themulti-peptide IMA901 vaccine was associated with
a clinical benefit. Over the next decade, immunotherapy trials in
kidney cancer will focus on learning how to combine PD-1/PD-L1
inhibitors with immune-modifying agents such as those targeting
the VEGF pathway (29, 30).
In this scenario, and with the possibility to introduce the
immune checkpoint inhibitors (ICI) in RCC patient treatment,
wemust consider the impact of TKIs on the immune systemof the
patient. TKIs currently approved for first-line treatment of mRCC
inhibit tumor cell growth and angiogenesis but also show
immune-regulatory effects. How these immune effects impact
subsequent immune-targeted therapies and affect treatment out-
come needs to be understood.
Several molecules and immune cell types are involved in the
interaction between the growing tumor and the immune system.
The balance between immunosuppression and immune activa-
tion dictates to some extent the prognosis and the response to
treatment, particularly for immune-based treatments. Several
biomarkers and or immune-molecular portraits have been stud-
ied in the attempt to identify responder patients, such as those
whomost likelywill benefit fromanti–PD-L1 treatment (31).One
of the mechanism of tumor silencing of immunity involves DCs,
themain orchestrators of the immune system (32, 33). DCs in the
tumor microenvironment may be tolerized and therefore unable
to present tumor antigens or unable to present antigens in the
appropriate setting within a costimulatory background. Several
molecules released by the tumor can induce this freezing effect
(34, 35). VEGF is one of them and this mechanism has been well
characterized in RCC (36). The immediate consequence of induc-
tion of tolerogenic DCs will be the lack of T-cell infiltration,
particularly tumor-specific T cells that represent the target for ICI
immunotherapy.
Results reported in this article show that the TKI pazopanib
could potentiate and differentiate human DCs. Immature and
mature DCs showed increased expression of HLA-DR, CCR7,
and CD40. PD-L1 decreased in the DCs after maturation, as
compared with untreated mature DCs or DCs differentiated in
the presence of sunitinib. PD-L1 was expressed in microvesicles
released by DCs confirming the role of cell particles in deliv-
ering remote signaling (37). The phenotypic changes observed
in the pazopanib-treated DCs were accompanied with biolog-
ical behavior consistent with an immune priming effect. IL10
production was reduced, whereas IL12 and CXCL10 production

























































































































DC phenotype obtained from TKI-treated patients. Comparison of iDCs and mDCs at T1 of pazopanib (black column) and sunitinib (gray column)
treatment. Data are reported as values of MFI  SD. Statistical significance was determined by Student paired t test.  , P < 0.01.
Zizzari et al.
Cancer Immunol Res; 6(6) June 2018 Cancer Immunology Research718
on August 29, 2020. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Published OnlineFirst April 26, 2018; DOI: 10.1158/2326-6066.CIR-17-0594 
Figure 6.
Immunological profile of six mRCC patients during TKI treatment. A, Swimmer Plot showing the clinical history and the blood sampling of six mRCC patients:
Patients 1, 2, and 3 treated with pazopanib, patients 4, 5, and 6 with sunitinib. B, Immunological analysis performed on PBMCs and sera collected from
blood samples for each patient. Sera were used to evaluate cytokines and chemokines released during TKIs treatment and analyzed by Luminex multiplex beads.
Immune cell subpopulations were monitored by flow cytometer and analyzed to FACSDiva Software. To analyze CD137þ T cells, lymphocytes were first
gated on FSC-A and SSC-A, then the CD3þ T-cell subpopulation was selected on lymphocytes. These CD137þCD3þ T cells were then selected and analyzed
for CD4 and CD8 (gating scheme in Supplementary Fig. S3B).
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amplified MLRs indicated an overall acquisition of immuno-
genicity by DCs.
DCs are the critical cells in immune activation as they are
responsible for antigen processing/presentation, cross-priming
and trafficking to the lymph nodes (38, 39). The pazopanib in
vitro and in vivo "treated" DCs, both from donors and from
patients, have all these hallmarks.
Sunitinib, another TKI used in mRCC treatment, did not have
the effects on DC differentiation as have been described by
others (11). Sunitinib and pazopanib have a similar pattern of
receptor recognition but display different affinities for VEGF-R1,
which could explain the diversity of immune modulation effect
(12). In particular, sunitinib affects the immunosuppressive
repertoire, Treg and MSDC, in RCC patients. The two drugs
appear, however, to be similar in terms of clinical outcome when
used in first-line therapy in mRCC (40, 41). Immunologically
this could be explained by arguing that one (pazopanib) is more
active in the rescue of DC from a tolerogenic state, inducing
activation signals, whereas the other (sunitinib) is more efficient
in making space for the antitumor effector cells by eliminating
immunosuppression in the microenvironment.
The consequences of receptor inhibition were studied in the
pazopanib-treated DC, as we investigated the signal transduc-
tion involved. We found that Erk signaling was shut down,
leading to downregulation of b-catenin. Wnt/b-catenin signal-
ing plays a role in cell differentiation, proliferation, survival, and
immune cell function. In tumors, the Wnt/b-catenin pathway is
activated in DCs leading to immune tolerance and immune
evasion. This results in suppression of effector T cells and
recruitment of Treg cells. Increased Wnt ligands released in the
tumor microenvironment activate b-catenin signaling in DCs,
resulting in production of IL10 and induction of tumor toler-
ance (22). In melanoma, intrinsic activation of the Wnt/
b-catenin pathway correlates with absence of T cells in the
microenvironment (42). The same pathway is involved in
bladder cancers, generating the non-T cell–inflamed tumors that
represent most cases in which tumors are unresponsive to ICI
therapy (43). A DC subtype is enriched in RCC that expresses
CD14, high TNFa, and low CXCL-10, which is responsible for
preventing a T-cell infiltrate from mediating antitumor func-
tions (35). Indeed, the presence of circulating, intratumoral, and
peritumoral CD14þ cells was a prognostic factor for decreased
survival in a cohort of 375 RCC patients (44).
Pazopanib can therefore have an antagonistic effect in the
tumor, releasing DCs from the tolerogenic/immature/CD14þ
state and tentatively restoring antitumor immune activation. The
goal of such therapy is to turn cold tumors into hot tumors, which
would be more responsive to ICI therapy. To understand if
pazopanib treatment could indeed exert this effect in vivo, we
utilized two different approaches. First, we selected CD14þ cells
from peripheral blood of mRCC patients during treatment with
pazopanib or sunitinib. The immune-priming effect of pazopanib
in DCs was confirmed. DCs derived from mRCC patients in
treatment with sunitinib expressed high amounts of CD14þ
marker and PD-L1. This may suggest no effect by sunitinib on
the DCs that remain in a more immature state as seen in other
cancer patients (44).
The second approachwas to longitudinally follow andmonitor
mRCC patients undergoing TKI therapy. This was not a homo-
geneous patient population because patients had different pre-
vious therapies, although all of them belong to the same risk
group. Nevertheless, we wanted to assess if we could detect
immunological changes in the peripheral blood that could be
associated with pazopanib treatment. Various conclusions are
supported although results are preliminary. First, patients 1, 2,
and 3 who received pazopanib showed a CD137þ T-cell popu-
lation. Patient 1 presented an ideal setting to study the effect of
pazopanib in vivo because this patient had no previous possibly
confounding therapy. Patient 2 had a recent radiotherapy to
control bone pain, which might have influenced the immune
system (45). Patient 3 is the only patient we have monitored
during anti–PD-1 nivolumab treatment. This patient had a drop
of CD137þ CD4þ T-cell population at time T4 and T5 just after
treatment with ICIs for progression. PD-1 expression also
decreased. This could be explained by recruitment of exhausted
T cells to the tumor or by difficulty in detecting PD-1 cells due to
the covering of the circulating nivolumab antibody.
CD137 (4-1BB, a member of the TNF-receptor family) is
considered a biomarker of tumor-reactive cells. The signaling
with its ligand or an agonistic antibody promotes expansion of
T cells, sustains survival, and enhances cytolytic function. This
marker has been used to select tumor-specific T cells and can be
upregulated in an antigen-dependent fashion (46, 47). Agonist
antibodies recognizing the CD137 receptor are part of the vast
repertoire of immune-modulatory antibodies being prepared
for the clinic. The Treg population was unchanged or diminished
in all mRCC patients. Immune monitoring on patient 4, the only
patient with recurrent mRCC we tested, showed the worst-case
scenario during sunitinib treatment, characterized by no CD137þ
T cells, high IL10, high percentages of Treg, low IL12, and
upregulation of CTLA-4 at 3 months of therapy.
The other consideration is the upregulation of checkpoint
inhibition markers on T cells as a sign of T-cell exhaustion. This
evaluation is relevant for clinical decisions because ICI are pro-
posed as second-line therapies for mRCC after TKIs. We saw
upregulation of CTLA-4 early in 2 of 3 sunitinib-treated patients.
In patient 5,we observed upregulation of bothCTLA-4 and Tim-3.
This patient progressed rapidly and died from the disease.
Pazopanib can have an immunological effect as early as the
secondmonth of treatment.Our experiencewith ICIs showed that
immune modifications can happen sooner than their impact on
the tumor becomes evident (48). Our data are part of an ever-
evolving clinical arena. CheckMate 214, a phase III, randomized,
open-label study evaluating the combination of nivolumab
(anti–PD-1) plus ipilimumab (anti–CTLA-4) versus sunitinib in
patients with previously untreated advanced or mRCC, showed
improved OS, ORR, and PFS in the nivolumab plus ipilimumab
group in intermediate/poor risk patients, with the greatest
improvements in those with PD-L1 expression on  1% of
biopsied tumor cells. These data suggest that ICIs could be used
as front-line treatment inmRCC even though only the knowledge
of the biological and immunological features of the tumor and
patient could indicate the best individual sequence/combination
of treatment.
In this context, we are recruiting mRCC patients with no
previous therapies and collecting tumor specimens to confirm
the immunological observations that we observed from this
preliminary study. Longitudinal study methods combined with
an individualized approach based on the immunological fitness
of the patient hold the greatest likelihood of clinical success.
Confounding influences that might affect the immune status of
the patient, such as other therapies, could limit our understanding
Zizzari et al.
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of the activity and efficacy of the immune-modulating agents we
wish to study.
In conclusion, the immune-priming effects of pazopanib
open therapeutic avenues for this TKI in the mRCC and
probably for other cancers. Variations of treatment sequences,
schedules, doses, and combinations with other TKIs or immu-
notherapy compounds or vaccines should be tested, taking
into account the immunological effects of TKIs and the
updated insights into oncology and the interactive tumor
microenvironment.
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